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OPSOMMING 
 
Inleiding:  Dit is welbekend dat toediening van insulien die hart beskerm 
teen ischemie/reperfusie-beserings, wat lei tot verbeterde hartfunksie. 
Hierdie effek word wyd ondersoek in modelle van ischemie en reperfusie. Dit 
is bewys dat ‘n verskeidenheid seintransduksie paaie, insluitend PI3-K, 
PKB/Akt, p70S6k en ERK, betrokke is by hierdie beskermende effek van 
insulien op die hart.  Baie min data is egter beskikbaar rakende die effek van 
insulien tydens normoksiese toestande. Alhoewel dit bekend is dat insulien ’n 
inotropiese effek op die normale geperfuseerde hart het, is die presiese 
sellulêre meganismes wat dit bewerkstellig nog nie nagevors nie.  Om dus ‘n 
beter begrip van hierdie meganismes te verkry is dit dus noodsaaklik om die 
effekte van insulien onder normoksiese perfusie toestande na te vors.  
Doelstellings:  Om ‘n geskikte dosis, waarby insulien sy positiewe 
inotropiese effek onder normale toestande het, vas te stel, om die moontlike 
meganismes betrokke by insulien-geïnduseerde verbetering in 
hartsametrekbaarheid te bestudeer, met spesifieke verwysing na die 
bloedvoorsiening en koronêre vloei, en om die moontlike betrokkenheid van 
die PI3-K pad en sy teiken effektore onder normale suurstof-toestande te 
ondersoek.  Materiaal en metodes:  Geïsoleerde rotharte is geperfuseer 
deur gebruik te maak van die Langendorff tegniek.  Na ‘n stabilisasie periode 
van 10 minute is rotharte blootgestel aan 30 minute perfusie met een van vier 
oplossings: ‘n standaard perfusie oplossing (Krebs-Henseleit buffer met 
glukose onder spesifieke gaskondisies van 95% O2, 5% CO2 – kontrole 
harte); standaard perfusie oplossing en insulien; standaard perfusie 
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oplossing met insulien en die stikstofoksied sintase inhibitor L-NAME, of 
standaard perfusie oplossing, met insulien en die PI3-K inhibitor wortmannin.  
Met verloop van die perfusie protokol, is ontwikkelde linker ventrikulêre druk 
(LVDevP), harttempo (HR) en koronêre vloei (CF), sowel as PI3-K en 
PKB/Akt fosforilasie, gemeet.  Resultate:  Toediening van insulien teen 
fisiologiese konsentrasies het ‘n verbeterde hartfunksie tot gevolg, in 
vergelyking met harte in die kontrole groep.  In teenstelling hiermee het harte 
wat insulien+L-NAME ontvang het ‘n betekenisvolle verlaagde funksie getoon 
in vergelyking met die kontrole harte en harte wat slegs insulien ontvang het 
(p<0.05).  Harte wat slegs insulien, of insulien+L-NAME ontvang het, het ‘n 
verhoging in gefosforileerde PKB/Akt (Thr308) getoon in vergelyking met 
kontrole harte.  Gefosforileerde PI3-K het ook geneig om hoër te wees in 
harte wat insulien+L-NAME of insulien+wortmannin ontvang het, as in harte 
wat slegs insulien ontvang het.  Gevolgtrekking:  Hierdie studie bewys dat 
fisiologiese konsentrasies van insulien, onder normale suurstof-toestande, ‘n 
positiewe inotropiese effek op hartfunksie uitoefen, soos gesien in die 
verbeterde LVDevP.  Wortmannin-geïnduseerde inhibering van die PI3-K pad 
het ‘n verlaagde PKB/Akt fosforilasie tot gevolg gehad in harte wat 
insulien+wortmannin ontvang het, terwyl die toediening van L-NAME die 
voordelige effekte van insulien op hartfunksie onderdruk het.  Hierdie 
resultate dui dus aan dat stikstofoksied ‘n rolspeler is in die positiewe 
inotropsiese effek van insulien op hartfunksie tydens normoksiese toestande,  
aangesien beide inhibitore hierdie effek onderdruk het.  Beide inhibitore het 
ook die betrokkenheid van stikstofoksied  en die PI3-K pad by die effek van 
insulien op harttempo en koronêre vloei onthul.  
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ABSTRACT 
Introduction: It is well documented that insulin offers cardioprotection 
against the consequences of ischaemia/reperfusion injury. Insulin-induced 
improvements in cardiac functions are widely investigated in models of 
ischaemia and reperfusion. It has been shown that many signalling pathways 
may be involved in the cardioprotection properties of insulin under those 
conditions. These pathways include PI3-K, PKB/Akt, p70S6k, ERK and many 
others. However, little data exists on the effects of insulin on the heart under 
normoxic condition. Some evidence has been presented that insulin has a 
positive inotropic effect on the normoxic perfused rat heart, but no precise 
cellular mechanism has been investigated or described in this regard. We 
believe that an investigation into the effects of insulin on cardiac function and 
pathways involved under normoxic conditions may help us to better 
understand the mechanisms of insulin-induced cardioprotection. Aims: To 
determine a suitable dose of insulin at which a positive inotropic response 
could be detectable under normoxic conditions, to investigate the possible 
mechanisms involved in insulin-induced increases in contractility with specific 
reference to the vasculature and the coronary flow and to investigate a 
possible involvement of PI3-K and its downstream effectors on the insulin 
effects on cardiac functions under normoxic conditions. Materials and 
methods: Isolated rat hearts were perfused retrogradely using the 
Langendorff technique. After 10 minutes of stabilization hearts were perfused 
for 30 minutes either with standard perfusion solution i.e. Krebs-Henseleit 
buffer + glucose gassed with 95%O2, 5%CO2 (control hearts), or with 
standard perfusion solution plus insulin alone or insulin together with the 
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nitric oxide synthase inhibitor L-NAME or the PI3-K inhibitor wortmannin. Left 
ventricular developed pressure (LVDevP), heart rate (HR) and coronary flow 
(CF) as well as phosphorylated PI3-K and PKB/Akt in heart were measured. 
Results: Administration of insulin alone at physiological concentrations 
showed improved cardiac function compared to hearts in the control group. 
Hearts that received insulin+L-NAME showed a significant decrease in 
function compared to the control hearts and the hearts that received insulin 
alone (p<0.05). Phosphorylated PKB/Akt (Thr308) was increased in hearts 
that received insulin alone and insulin+L-NAME compared to the control 
hearts. Phosphorylated PI3-K tended to be higher in hearts where insulin was 
administered alone compared to the hearts that received insulin+L-NAME or 
insulin+wortmannin. Conclusion: This study confirmed that physiological 
concentrations of insulin exert positive inotropic effects on cardiac function in 
normoxic perfused rat hearts as seen with the improved LVDevP. Inhibition of 
PI3-K by wortmannin induced a decrease in phosphorylated PKB/Akt in 
hearts that received insulin+wortmannin and administration of L-NAME 
impaired the beneficial effects of insulin on cardiac functions. Therefore these 
results may indicate that nitric oxide may have a role in the positive effect of 
insulin on cardiac function in the healthy heart perfused under normoxic 
conditions. L-NAME as well as wortmannin reversed the positive inotropic 
effects of insulin. Both inhibitors also unmasked effects of insulin via nitric 
oxide and PI3-K on heart rate and coronary flow. 
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RESUME 
Introduction: La documentation sur l’insuline et ses  propriétés 
cardioprotectives est vaste. Les améliorations induites par l’insuline des 
fonctions cardiaques sont largement étudiées sur des modèles 
ischémie/reperfusion. Il a été démontré que plusieurs voies de signalisation 
peuvent être impliquées dans les propriétés de cardioprotection de l'insuline 
dans ces conditions. Ces voies incluent PI3-K, PKB/Akt, p70S6k, ERK et 
beaucoup d'autres. Cependant, peu de données existent sur les effets de 
l'insuline sur le coeur dans sous des conditions normales. Des évidences ont 
été présentée sur le fait que l'insuline a un effet inotropique positif sur le 
coeur perfusé de rats sous les conditions normales, mais aucun mécanisme 
cellulaire précis n'a été étudié ou décrit à cet égard. Nous croyons qu'une 
investigation sur les effets de l'insuline sur la fonction cardiaque sous les 
conditions normales et les voies impliquées peut nous aider à mieux 
comprendre les mécanismes de cardioprotection induite par l’insuline. But : 
Déterminer une dose d'insuline appropriée avec laquelle une réponse 
inotropique positive pourrait être discernable sous des conditions normales, 
étudier les mécanismes possibles impliqués dans l’accroissement induite par 
l’insuline de la contractilité avec un regard spécifique sur la vascularisation et 
l'écoulement coronaire, étudier une l’implication possible de PI3-K et de ses 
effecteurs sur les effets de l’insuline sur les fonctions cardiaques dans des 
conditions normales. Matériels et méthodes : Des coeurs isolés de rats ont 
été perfusés de manière rétrograde en utilisant la technique de Langendorff. 
Après 10 minutes de stabilisation, les coeurs ont été perfusés pendant 30 
minutes avec la solution standard de perfusion, c’est-à-dire la solution 
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tampon de Krebs-Henseleit + glucose aérée  avec 95%O2, 5%CO2 (coeurs 
de control), ou avec la solution standard de perfusion plus l’insuline seule ou 
l’insuline associée à l’inhibiteur de l’oxyde nitrique synthéase L-NAME ou à 
l’inhibiteur de PI3-K wortmannin. Pression développée ventriculaire gauche 
(LVDevP), fréquence cardiaque (HR) et écoulement coronaire (CF) aussi 
bien que PI3-K et PKB/Akt phosphoreux des coeur ont été mesurés. 
Résultats : L'administration de l'insuline seule aux concentrations 
physiologiques a montré des fonctions cardiaques améliorées comparées 
aux coeurs du groupe de control. Les coeurs qui ont reçus l'insuline+L-NAME 
ont montré un décroissement significatif des fonctions comparés aux coeurs 
de control et aux coeurs qui ont reçu l'insuline seule (p< 0.05). PKB/Akt 
(Thr308) phosphoreux a augmenté chez les coeurs qui ont reçus l'insuline 
seule  et l'insuline+L-NAME comparés aux coeurs de control. PI3-K 
phosphoreux a tendance à être plus élevé dans les coeurs où l'insuline seule 
a été administrée comparé aux coeurs qui ont reçus l’insuline+L-NAME ou 
l’insuline+wortmannin. Conclusion : Cette étude a confirmé que les 
concentrations physiologiques de l'insuline exercent des effets inotropiques 
positifs sur les fonctions cardiaques des coeurs perfusés normaux de rats 
comme l’a montré la pression amélioré du ventricule gauche (LVDevP). 
L'inhibition de PI3-K par le wortmannin a induit une diminution de PKB/Akt 
phosphoreux dans les coeurs qui ont reçus l’insuline+wortmannin et 
administration de L-NAME a altéré les effets bénéfiques de l'insuline sur les 
fonctions cardiaques. Ces résultats peuvent indiquer, par conséquent, que 
l'oxyde nitrique peut avoir un rôle dans l'effet positif de l'insuline sur les 
fonctions cardiaques du coeur saint perfusé dans des conditions normales. 
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L-NAME, aussi bien que le wortmannin,  a renversé les effets inotropiques 
positifs de l'insuline. Les deux inhibiteurs ont également démasqué des effets 
d'insuline par l'intermédiaire de l'oxyde nitrique et le PI3-K sur l'écoulement 
coronaire et la fréquence cardiaque. 
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CHAPTER 1 
 
INTRODUCTION 
 
It is widely recognized that the heart is the centre of circulation and is the 
seat of blood circulation within the body. The heart is an organ composed of 
four chambers, which work closely together. Oxygenated blood from the 
lungs enters the heart through the left atrium from where it is then pumped 
into the left ventricle. The filling of the left ventricle occurs during the 
relaxation phase, known as diastole. The left ventricle empties during its 
contraction (systole) to facilitate blood circulation in the entire body. 
Deoxygenated blood from the venous system then re-enters the heart 
through the right atrium, from where it is pumped into the right ventricle, from 
where blood is sent back to lungs in order to pick up oxygen and off-load 
carbon dioxide (Opie, 3rd edition, p8 and 9). 
 
Most of the heart is made up of contractile muscle cells (myocytes) known as 
cardiomyocytes. Myocytes constitute about 75% of the total volume of the 
myocardium (Brilla et al. 1991); however they are not the most numerous in 
the organ. The major function of cardiomyocytes is to contract to facilitate the 
pumping action of the heart. The two main contractile proteins in the heart 
are the thick myosin filaments and the thin actin filaments that slide over 
each other during contraction (Opie. 3rd edition, p45). The breakdown of 
adenosine triphosphate (ATP) is the only source of energy for contraction 
and other vital functions. The major fuels, in order of importance in the 
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healthy heart, are free fatty acids, glucose and lactate. These are 
transformed to acetyl-CoA, which enters the citric acid cycle to produce 
NADH2 (NADH + H+) (Opie. 3rd edition, p311). 
 
Insulin is a polypeptide hormone that is produced and secreted by the β cells 
in the pancreas. Insulin exerts a myriad of biological actions, including 
regulation of glucose uptake and utilisation, protein and lipid synthesis, and 
gene transcription. It is the primary hormone involved in glucose 
homeostasis, and an absolute or relative lack of its secretion or action leads 
to impaired glucose metabolism and diabetes (for review, see Srivastava 
1998). 
 
The knowledge of various aspects of insulin action has increased significantly 
during the past several years, and many signalling steps involved in insulin 
action have been identified (White and Kahn, 1994). In addition, insulin has 
been used to improve the efficiency of energy production and recovery of 
contractile function in the damaged heart (Taegtmeyer & Villalobos 1995). 
 
The biological actions of insulin are initiated by the binding of insulin to its 
receptor, which is located on the outer surface of the membrane of cells 
within insulin target tissues. 
 
The insulin receptor (IR) is a hetero-tetrameric glycoprotein composed of two 
135-kDa extracellular α-subunits and two 95-kDa transmembrane β-subunits. 
The α-subunits possess the insulin binding activity whereas the β-subunits 
 15 
have an intrinsic protein tyrosine kinase activity. The binding of insulin to the 
α-subunit of the receptor activates the tyrosine kinase and results in 
phosphorylation of tyrosine residues of the β-subunit. This phosphorylation 
subsequently activates several endogenous substrates including insulin 
receptor substrates (IRS) (Onoda et al., 1989) and related proteins and src-
homology 2 (SH2)-domain containing adaptor protein (Shc) (for review see 
Brownsey, 1997; Srivastava, 1998). 
 
Insulin was first used as a polarising agent for the heart in early 60’s by Sodi-
Pallares et al. in a mixed cocktail of glucose, insulin and potassium for the 
treatment of acute myocardial infarction (AMI). The use of insulin then shifted 
to a more metabolic approach since it has the ability to improve the energy 
production efficiency by increasing glucose uptake and glucose utilisation to 
improve recovery of contractile function, and to lower the content of free fatty 
acids (FFA) in the serum (Sidossis et al. 1996; Taegtmeyer & Villalobos; 
1995). 
 
In mammalian heart and in isolated cardiac muscle preparations, insulin 
exerts a positive inotropic effect (that is to say it increases the force of 
contraction of the cardiac muscle). These positive effects on the heart include 
increases in maximum force generation, improvements in post-ischaemic 
contractile functions when administered during low flow ischaemia and at 
reperfusion (Doenst et al. 1999, Baines et al. 1999; Jonassen et al. 2001; 
Legtenberg et al. 2002; Van Rooyen et al. 2002; Fischer-Rasokat & Doenst 
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2003), increases in cardiac output and faster relaxation in both experimental 
and clinical situations (Reviewed by Aulbach, 1999). 
 
Among the immediate targets of the insulin receptor, the most extensively 
studied has been the insulin-receptor substrate-1 (IRS-1). Originally 
observed as a prominent 185-kDa phosphoprotein, this soluble protein 
becomes phosphorylated in response to insulin on at least 8 out of 20 
potential tyrosine phosphorylation sites. These sites occur within Y–X–X–M 
motifs which are recognized by several defined proteins which contain SH2 
(src-homology 2) domains. IRS-1 therefore appears to act as a nucleation 
site for the assembly of subsequent downstream signalling proteins. Proteins 
with SH2 domains which associate with IRS-1 include the adaptor proteins 
Grb2 and Nck, the protein tyrosine phosphatase SH-PTP2/Syp and p85, the 
85-kDa regulatory subunit of PI-3-kinase (See Fig. 1.1, p17). 
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Figure 1.1: Overview of the pathways involved in insulin signalling (Adapted from Shepherd 
P.R., 1996). 
 18 
Insulin signalling is mediated by complex multiple cascade pathways 
characterised by spatial and temporal aspects (Coffer et al. 1998; Hue et al. 
2002). After the binding of insulin to the insulin receptor (IR), the tyrosine 
kinase activity of IR leads to IR auto-phosphorylation and to the subsequent 
phosphorylation of insulin receptor substrates (IRS). One of the downstream 
signalling pathways of IRS involves the activation of phosphatidylinositol 3-
kinase (PI3-K) and its recruitment by phosphorylated IRS. PI3-K produces 
phosphatidylinositol 3,4,5-tris-phosphate [Ptdlns(3,4,5)-P3] and 
phosphatidylinositol 3,4-bis-phosphate [Ptdlns(3,4,-P2], which bind to the 
pleckstrin homology (PH) domain of at least two different serine/threonine 
protein kinases, namely phosphoinositide-dependent protein kinase-1 (PDK-
1) and protein kinase B (PKB, also known as Akt) (Coffer et al. 1998; Hue et 
al. 2002), (See Fig. 1.2, p19). 
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Figure 1.2: Mechanism of activation of PKB/Akt (Adapted from Nicholson and Anderson, 
2002). 
 
In un-stimulated cells PKB/Akt is not phosphorylated on Thr308 or Ser473 and resides mainly 
in the cytosol. Following growth factor (GF) activation of receptor tyrosine kinases (RTKs, or 
other cell surface receptors, not shown), PI-3K is recruited to the receptor and activated, 
resulting in the production of PIP3. This recruits PKB/Akt to the membrane where it is 
phosphorylated on Thr308 within the catalytic domain by PDK-1 and on Ser473 within the 
regulatory domain by an ill-defined mechanism, possibly involving (a) auto-phosphorylation, 
(b) PDK-1, (c) ILK, or (d) an unidentified PDK-2. PKB/Akt is then released from the 
membrane and translocates to other sub-cellular compartments. 
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PDK-1 and PDK-2 participate in the phosphorylation and activation of several 
downstream protein kinases including PKB/Akt and p70S6K. PKB/Akt 
mediates most short-term effects of insulin which include among others: 
(i) The stimulation of glycogen synthesis by phosphorylation 
and inactivation of glycogen synthase kinase 3 (GSK-3) 
(Coffer et al., 1998) 
(ii) Glucose uptake through the recruitment of glucose 
transporters 4 (GLUT4) to the plasma membrane 
(Lawrence, 1992); 
(iii) The activation by phosphorylation of phosphodiesterase 3B 
(PDE 3B, the enzyme responsible for the anti-cyclic 
adenosine monophosphate (anti-cAMP) effects of insulin) 
(Wijkander at al. 1998); 
(iv) The inhibition of apoptosis by phosphorylation and 
inactivation of Bad (a pro-apoptotic protein). (Del Peso et al, 
1997; Datta et al., 1997). See Fig. 1.3, p21. 
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Figure 1.3: Insulin Signalling.  
 
INS = insulin, RTK = receptor tyrosine kinase, IRS = insulin receptor substrate, P = 
phosphorylation sites, PI3-K = phosphatidylinositol kinase-3, PH = pleckstrin homology, 
PDK1/2 = phosphatidyl inositol dependent kinase-1/2, PKB/Akt = protein kinase B, GSK-3 = 
glycogen synthase kinase-3, PFK = phosphofructo kinase-2. GLUT4 = glucose transport, 
BAD = pro-apoptotic protein, Wortmannin = PI3-K inhibitor. 
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One of the pathways involved in the insulin cardioprotection is via 
phosphatidylinositol 3-kinase (PI3-K), which is an heterodimer consisting of a 
85 kDa regulatory subunit and a 110 kDa catalytic subunit (Kitamura et al. 
1998). PI3-K is part of the cascade that activates the serine/threonine kinase 
Protein kinase B (also known as Akt – PKB/Akt). Most of the different 
pathways that are activated by Akt are hypothesized to promote cell survival 
(Matsui et al., 2001)  
 
Studies have shown that insulin, as well as other factors such as ischaemia, 
stimulate glucose uptake in isolated perfused rat hearts. Glucose is the most 
used substrate for the hearts perfused in the Langendorff method (for explicit 
review see Brownsey et al., 1997). Transport of glucose into the myocardial 
cells is mediated by the glucose transporter (GLUT) isoforms GLUT-4 and 
GLUT-1. The translocation of GLUTs has been demonstrated in isolated 
cardiac myocytes (Slot, 1991), in perfused hearts (Watanabe, 1984), and in 
the heart in vivo (Uphues et al., 1994). 
 
The GLUT-4 isoform is localised mainly on intracellular membrane vesicles in 
the basal state and translocates to the plasma membrane in response to 
stimuli (Kolter et al. 1992; Egert et al. 1999). GLUT 4 is insulin sensitive and 
is translocated to the sarcolemma where it mediates increased glucose 
uptake into the myocyte when stimulated by insulin (Stanley et al. 1997; King 
& Opie 1998; Charron & Katz 1998). 
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Insulin is also involved in the regulation of glycolysis in the heart. Regulation 
of the glucose transporter GLUT-4 and programmed cell death activity has an 
important bearing on flux through glycolysis which is generally coordinated 
with rates of pyruvate oxidation, increasing in response to insulin and to 
increased cardiac workload during glucose perfusion (reviewed by Brownsey 
et al., 1997). 
 
It is known that exogenous insulin protects the heart against ischaemia-
reperfusion injury of the myocardium (Sodi-Pallares et al. 1962; Apstein et al. 
1983; Oliver & Opie 1994) and there is evidence for clinical efficacy when 
insulin is given as glucose-insulin-potassium (GIK) (Diaz et al. 1998). 
 
Louw (2001) investigated the cardioprotective effects offered by insulin in the 
ischaemia/reperfusion isolated rat heart model (Louw 2001, Unpublished 
results, MSc thesis). The study demonstrated and confirmed that insulin 
administration before, during and after low flow ischaemia, offered 
cardioprotection that was reflected by improved functional performance 
during reperfusion and by delayed of time to onset of ischaemic contracture 
(Louw 2001, Unpublished results, MSc thesis). Insulin has also been shown 
to reduced the infarct size (Jonassen et al. 2000) in the in vivo rat heart, and 
provided better cardiac reperfusion recovery in working heart (Van Rooyen et 
al. 2002). 
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AIMS 
 
Insulin-induced improvements in cardiac functions are widely investigated in 
models of ischaemia and reperfusion. It has been shown that many signalling 
pathways may be involved in the cardioprotection effect of insulin under 
those conditions. These pathways include PI3-K, PKB/Akt, p70S6K, ERK and 
many others. However, little data exists on the effects of insulin on the heart 
under normoxic condition. We therefore hypothesize that insulin may improve 
cardiac function under normoxic conditions and we believe that an 
investigation into the effects of insulin on cardiac function and pathways 
involved under normoxic conditions may help us to better understand the 
mechanisms of insulin-induced cardioprotection. Therefore, our study aimed 
to: 
 
 Determine a suitable dose of insulin at which a positive inotropic 
response could be detectable under normoxic conditions. This was 
achieved by perfusing the hearts with three different concentrations of 
insulin. 
 
 Investigate the possible mechanisms involved in insulin-induced 
increases in contractility with specific reference to the vasculature and 
the coronary flow. A specific regard was given to nitric oxide. 
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 Investigate a possible involvement of PI3-K and its downstream 
effectors on the insulin effects on cardiac functions under normoxic 
conditions. 
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C h a p t e r  2  
LITERATURE REVIEW 
Background on insulin involvement in cardiac therapy. 
The heart uses various substrates, eg. fatty acids and glucose, for the 
production of high-energy phosphates. During ischaemia, glucose becomes 
the preferred substrate as glycolysis switches from aerobic to anaerobic 
conditions. Glucose transport into myocardial cells is mediated by the glucose 
transporter (GLUT) isoforms GLUT-4 and GLUT-1. GLUT-4 is predominant in 
the heart and is localised mainly on intracellular membrane vesicles in the 
basal state and translocates to the plasma membrane in response to stimuli 
such as insulin, ischaemia, and contraction (Kolter et al. 1992; Egert et al. 
1999). 
 
The effects of insulin on energy production and recovery of contractile 
function in the heart following ischaemia and reperfusion is well known 
(Taegtmeyer & Villalobos 1995). Sodi-Pallares et al. (1962) were the first to 
use insulin in a mixed cocktail containing glucose, insulin and potassium 
(GIK) for the treatment of acute myocardial infarction (AMI) (Sodi-Pallares et 
al. 1962). 
 
This GIK cocktail was first advocated as a polarizing solution (Legtenberg et al. 
2002; Sundell & Knuuti 2003). Due to the ability of insulin to lower the content 
of free fatty acids (FFA) in serum via the inhibition of the adipose tissue 
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triacylglycerol lipase and to enhance glucose utilisation (Sidossis et al. 1996) it 
was argued that it could also be a metabolic treatment. 
 
Braimbridge et al. (1969) were the first to clinically use GIK infusion in cardiac 
surgery and they reported that the cocktail was successful in treating patients 
with low cardiac output after mitral valve replacement, who were not 
responding to the treatments available at the time (isoprenaline, digoxin or 
pacemaking) (Braimbridge et al. 1969). 
 
However, during the later part of the 1960’s a working group from the British 
Medical Research Council failed to demonstrate any benefit of GIK in the 
treatment of myocardial infarction (Medical Research Council Working Party 
on the Treatment of Myocardial Infarction 1968). This prevented the 
combination of GIK from becoming a standard treatment for patients with 
acute myocardial infarction. In a recent review Doenst et al. (2003) focused on 
the analysis of insulin based research, and found that about 81% out of 91 
study protocols using insulin or GIK for the heart reported a benefit of the 
insulin treatment while only 19% failed to prove the benefit of insulin. Doenst et 
al. (2003) mentioned that none of the studies that failed to demonstrate a 
benefit of insulin reported the occurrence of any life-threatening complications 
(Doenst et al. 2003). 
 
Despite the positive observations, the benefit of insulin had still not been 
noticed and/or validated by the British Medical Research Council and by some 
researchers. It is only recently that the concept of GIK has attracted renewed 
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attention after recent studies that demonstrated a reduction in 1-year mortality 
for diabetic patients with acute myocardial infarction (Malmberg et al. 1995; 
Fath-Ordoubadi & Beatt 1997). 
 
The renewed interest in GIK as a therapy was also due to results showing a 
direct positive inotropic effect of insulin on the post-ischaemic heart (Doenst et 
al. 1999) in Sprague-Dawley rat heart, or reduction in infarct size. These 
findings have been confirmed by other groups that used other experimental 
models including rabbits and Wistar rats  (Baines et al. 1999; Jonassen et al. 
2001). 
 
Studies have shown that GIK reduces the infarct size and improves recovery 
of mechanical function in rat and dog hearts with myocardial infarction (Ahmed 
et al. 1978, Jonassen et al. 2000a). Because of these observations, it was 
thought that the beneficial effects of GIK in myocardial ischaemia may result 
from increased myocardial glucose uptake and glycogen content, providing 
additional stores of substrate for glycolytic energy generation (Maroko et al. 
1972; Ahmed et al. 1978; Jonassen et al. 2000; Huisamen et al. 2001). 
 
The benefit of GIK has also been attributed to its ability to reduce circulating 
levels and myocardial uptake of FFA, since increased FFA levels are toxic to 
the ischaemic myocardium and are associated with increased membrane 
damage, arrhythmias, and decreased cardiac function in vivo (Opie & Owen 
1976; Apstein 1998). 
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Under physiological conditions, insulin controls numerous metabolic processes 
in various targeted tissues, largely through the receptor-mediated tyrosine 
phosphorylation of insulin receptor substrates 1 and 2 (IRS-1/2) and possibly 
other adapter proteins. This results in activation of IRS-1/2 dependent 
phosphatidylinositol 3-kinase (PI3-K) and its downstream effectors, protein 
kinase B (PKB, also known as Akt) and atypical protein kinase C (aPKC) 
(Takata et al. 1999, Bandyopadhyay et al. 2000). In studies conducted on 
muscles and adipocytes regarding insulin’s action on cells, it appears that both 
aPKC and Akt control glucose transport, in addition to Akt regulating glucose 
storage in the form of glycogen (Kohn et al. 1996; Bandyopadhyay et al. 1997; 
Takata et al. 1999; Hill et al. 1999; Bandyopadhyay et al. 2000). See Fig. 2.1, 
p27. 
 
Previous studies on insulin action in the heart. 
Insulin is a well known vasodilator and has positive inotropic effects, and 
hence improves post-ischaemic contractile function of the heart when given 
during low flow ischaemia and at reperfusion in both experimental and clinical 
situations (Jonassen et al. 2001; Legtenberg et al. 2002; Van Rooyen et al. 
2002; Fischer-Rasokat & Doenst 2003). 
 
Benefit of insulin on contractility 
Insulin has been shown by several groups to improve the recovery of 
contractile function of the heart after a no flow and/or a low flow ischaemia 
(Ahmed et al. 1977, Tomai et al. 1999; Jonassen et al. 2001; Legtenberg et 
al. 2002; Van Rooyen et al. 2002). In her protocol, Louw observed an 
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increase in the left ventricular developed pressure (LVDevP) in the control 
hearts that received insulin (Louw 2001, Unpublished results, MSc thesis).  
 
Insulin signalling is an important regulator of substrate metabolism in 
vertebrates. In the healthy heart, insulin has direct effects on glucose 
transport (Abel et al. 1999; Belke et al. 2001), glycolysis (Depre et al. 1998), 
glucose oxidation (Patti & Kahn 1998), glycogen synthesis (Laughlin et al. 
1992), and protein synthesis (Flaim et al. 1983). 
 
Glucose transport  
Myocardial glucose metabolism is dependent on the uptake of extracellular 
glucose, which is regulated by the transmembrane glucose gradient and the 
activity of glucose transporters GLUT-1 and GLUT-4. In the heart, GLUT-1 is 
relatively insulin insensitive and is considered to be responsible for basal 
glucose uptake in the setting of low fasting insulin concentrations and normal 
conditions. GLUT-4, which is insulin sensitive, is distributed to a greater extent 
in the intracellular vesicles under normoxic conditions. On stimulation by 
insulin or ischaemia, GLUT-4 is translocated to the sarcolemma where it 
mediates increased glucose uptake into the myocyte (Stanley et al. 1997; King 
& Opie 1998; Charron & Katz 1998). 
 
Activation of PKB/Akt by insulin leads to the protection of the myocardium via 
various processes among which the translocation of glucose transporters to 
increase glucose uptake (Lawrence, 1992). 
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Figure 2.1: Pathways involved in insulin-mediated increase of glucose uptake 
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The action of insulin on the cell is initiated by the binding of insulin to its 
receptor which results in the stimulation of the insulin receptor’s intrinsic 
tyrosine kinase activity. This mediates auto-phosphorylation of the receptor 
and subsequent phosphorylation of substrate proteins on multiple tyrosine 
residues. The major substrates of the insulin receptor (IR) are the insulin 
receptor substrate (IRS) proteins IRS-1, IRS-2, IRS-3 and IRS-4, but the 
most investigated are IRS-1 and IRS-2 (Sun et al. 1991; Sun et al. 1995; 
Lavan et al. 1997a; Lavan et al. 1997b). 
 
Insulin administration before ischaemia 
Apstein et al. (1983) showed that high glucose and insulin administration 
during moderate but not severe ischaemia has a protective effect on the 
heart. This observation was also confirmed by Van Rooyen et al. (2002). In 
their study, Apstein et al. (1983) observed that the beneficial effects of the 
glucose and insulin administration during moderate ischaemia were: 
- Improved contractile function during the post-ischaemic recovery 
period, 
- The prevention of contracture during ischaemia, 
- The lesser degree of contracture during recovery, and 
- The higher level of myocardial adenosine triphosphate (ATP) 
during the ischaemic period. 
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Insulin administration at reperfusion 
Focusing on the effect of insulin on the heart at reperfusion, Jonassen et al. 
(2000) demonstrated that in rat neonatal cardiomyocytes, administration of 
insulin at the onset of reoxygenation following a simulated ischaemic insult 
resulted in a significant reduction both in total myocyte death and in the 
development of apoptosis compared to models where insulin was 
administered to the whole heart before or during low flow ischaemia 
(Jonassen et al. 2000a). In the isolated, perfused heart, these cardio-
protective effects of insulin seemed to be mediated via the tyrosine kinase 
and phosphatidylinositol 3-kinase (PI3-K) signalling pathways since the 
protective effect observed with insulin at reperfusion was completely 
abolished when the hearts were treated with lavendustin-A (a tyrosine kinase 
inhibitor, 0.1 μmol/L was used) or with wortmannin (a PI3-K inhibitor, 1 
μmol/L was used) (Jonassen et al. 2001). This suggested that insulin 
improves post-ischaemic recovery of function through PI3-K. In addition, 
insulin increases cardiac contractility and has an anti-apoptotic effect on 
cardiomyocytes (Jonassen et al. 2001; Louw 2001, Unpublished results, MSc 
thesis). 
 
In vivo, many of the effects of insulin on cardiac metabolism and function are 
related to the systemic effects of insulin, such as increased peripheral and 
coronary vasodilatation (Baron 1994), increased sodium and water uptake by 
the kidneys (DeFronzo 1981), and changes in the delivery of substrates to 
the heart (Brownsey et al. 1997; Jagasia et al. 2001). For example, insulin’s 
anti-lipolytic effect will reduce the delivery of FFAs to the heart, which in 
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conjunction with increased intracellular Malony-coenzyme A levels, reduces 
fatty acid oxidation rates (Awan & Saggerson 1993). 
 
Effects of insulin on cardiac function  
A key physiological action of insulin is the stimulation of glycogen synthesis, 
involving an increase in the glucose uptake and activation of the enzyme 
glycogen synthase (GS). Insulin has been demonstrated to cause inactivation 
of glycogen synthase kinase-3 (GSK-3) in several cell types; and in rabbits in 
vivo (Welsh & Proud 1993; Cross et al. 1994; Borthwick et al. 1995). 
 
As the 90 kDa ribosomal S6 kinase p90rsk (also called MAPKAP kinase 1 or 
rsk-2) can phosphorylate and inactivate GSK-3 in vitro and as it lies 
downstream of the insulin-stimulated mitogen activated-protein (MAP) kinase 
cascade it provides an attractive mechanism whereby insulin could stimulate 
GS by both activation of protein phosphatase 1 (PP 1) and inactivation of 
GSK-3 (Sutherland & Cohen 1994; Seger & Krebs 1995). 
 
Some studies have also demonstrated that activation of GS, inactivation of 
GSK-3 and stimulation of glucose uptake by insulin are blocked by 
wortmannin (a fungal inhibitor of phosphatidylinositol 3-kinase) placing the 
relevant pathway(s) downstream of that enzyme (Arcaro & Wymann 1993). 
One must also consider that the time span where insulin effects on the heart 
can be observed depends on the dose and model used. Hurel et. al. (1996) 
have shown for example that it takes less than 10 min to observe insulin 
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effects on cultured human myoblasts from the gastrocnemius muscle 
(skeletal muscle) of healthy subjects (Hurel et al. 1996). 
 
Ischaemia and cardiac function 
Myocardial ischaemia takes place when there is a reduction of the coronary 
flow resulting in an inadequate oxygen supply to the tissue. It is a multi-
factorial process characterised by several changes like loss of energy, 
membrane damage, and metabolite accumulation (Opie 1998, p515). 
 
Reperfusion of the ischaemic heart improves cardiac metabolism by 
increasing contractile activity and the washout of harmful products (Neely & 
Grotyohann 1984). Reperfusion also provides the heart with oxygen and 
substrate. Despite its beneficial effects on the ischaemic heart, reperfusion 
might also induce cell injury by worsening the injury sustained during 
ischaemia (Tennant & Wiggers 1935). These injuries which may include 
arrhythmias, fibrillation and myocardial stunning, may have a deleterious 
impact on cardiac function at reperfusion (Bolli 1991; Reimer et al. 1993). 
 
Signalling Pathways involved in insulin cardioprotection 
Insulin signalling is mediated by complex multiple cascade pathways 
characterised by spatial and temporal aspects. Previous work on tissues and 
cells showed that insulin signalling is initiated by its binding to the insulin 
receptor (IR) (Coffer et al. 1998; Hue et al. 2002). This activates the tyrosine 
kinase activity of IR leading to IR auto-phosphorylation and to the 
subsequent phosphorylation of insulin receptor substrates (IRS). One of the 
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downstream signalling pathways of IRS involves the activation of 
phosphatidylinositol 3-kinase (PI3-K) and its recruitment by phosphorylated 
IRS. Phosphorylation of PI3-K produces phosphatidylinositol 3,4,5-tris-
phosphate [Ptdlns(3,4,5)-P3] and phosphatidylinositol 3,4-bis-phosphate 
[Ptdlns(3,4)-P2], which bind to the pleckstrin homology (PH) domain of at 
least two different serine/threonine protein kinases, namely phosphoinositide-
dependent protein kinase-1 (PDK-1) and protein kinase B (PKB, also known 
as Akt) (Coffer et al. 1998; Hue et al. 2002). 
 
PDK-1 participates together with PDK-2 in the phosphorylation and activation 
of several downstream protein kinases including Akt and p70S6K. Akt 
mediates most short-term effects of insulin which include among others: 
(i) The stimulation of glycogen synthesis by phosphorylation 
and inactivation of glycogen synthase kinase 3 (GSK-3) 
(Coffer et al., 1998); 
(ii) Glucose uptake through the recruitment of glucose 
transporters 4 (GLUT4) to the plasma membrane 
(Lawrence, 1992); 
(iii) The activation by phosphorylation of phosphodiesterase 3B 
(PDE 3B, the enzyme responsible for the anti-cyclic 
adenosine mono phosphate (anti-cAMP) effects of insulin) 
(Wijkander et al., 1998); 
(iv) The inhibition of apoptosis by phosphorylation and 
inactivation of Bad (a pro-apoptotic protein) (Del Peso et al., 
1997; Datta et al., 1997). 
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The stimulation of heart glycolysis by insulin is due to the concomitant 
recruitment of GLUT4 and an increase in fructose-2,6-P2 concentration which 
itself results from phosphofructo kinase-2 (PFK-2) activation. Insulin has an 
important role in normal vascular function. In healthy subjects, insulin 
increases not only blood flow but also blood volume in skeletal muscle, 
classifying insulin as a true vasodilatory hormone (Raitakari et al. 1995; 
Mather et al. 2001; Hue et al. 2002). 
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The protein kinases 
The signalling pathways that determine myocardial susceptibility to injury 
during ischaemia and reperfusion include protein phosphorylation and those 
pathways that may regulate myocyte loss through programmed cell death 
(Jonassen et al. 2001). 
 
Protein kinase B/Akt 
Protein kinase B, also known as serine-threonine kinase Akt, (PKB/Akt) is a 
member of the second messenger-dependent family of serine/threonine 
kinases that have been implicated in the signalling pathways downstream of 
the growth factor receptor tyrosine kinases (Meier et al. 1997; Nicholson & 
Anderson 2002). PKB/Akt activation is induced by several growth factors 
including nerve growth factor (NGF), platelet-derived growth factor (PDGF), 
basic fibroblast growth factor such as β fibroblast growth factor (βFGF) and 
heparin binding growth factor (HBGF), insulin and insulin-like growth factor-1 
(IGF-1) (Franke et al. 1997; Downward 1998). 
 
PKB/Akt is a downstream effector of phosphatidylinositol-3 kinase (PI3-K). It 
was originally cloned as the human homologue of (Stool et al.,. 1977) v-akt, a 
retrovirus associated (Akt8) oncogene. Akt is a multifunctional signalling 
intermediate in the regulation of apoptosis, cell cycle progression, and energy 
metabolism. Three mammalian isoforms of Akt – Akt1 (PKBα), Akt2 (PKBβ) 
and Akt3 (PKBγ) exist. Akt is expressed ubiquitously with elevated 
expression in brain, heart and lungs (Johnson 1988; Jones et al. 1991; Brazil 
& Hemmings 2001; Scheid & Woodgett 2001) 
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All three isoforms of PKB/Akt share three domain structures consisting of an 
N-terminal pleckstrin homology (PH) domain, followed by a kinase domain 
related to protein kinases A and C (containing Thr308 in Akt1), and a C-
terminal regulatory domain (containing Ser473 in Akt1) (Franke et al. 1997; 
Scheid & Woodgett 2001). PH domains of Akt have high-affinity recognition 
of phosphoinositide head groups. 
 
Activation of PI3-K leads to phosphorylation of membrane phosphatidyl 
inositol-4,5-bis-phosphate [PtdIns(4,5)-P2], generating phosphatidylinositol-
3,4,5-tris-phosphate [PtdIns(3,4,5)P3] and phosphatidylinositol-3,4,-bisphos-
phate [PtdIns(3,4)P2]. 
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Figure 2.2: Mechanism of activation of PKB/Akt. 
  
In unstimulated cells PKB/Akt is not phosphorylated on Thr308 or Ser473 and resides mainly in the cytosol. Following growth factor (GF), 
insulin and insulin-like growth factor-1 (IGF-1) activation of receptor tyrosine kinases (RTKs, or other cell surface receptors, not shown), 
PI-3K is recruited to the receptor and activated, resulting in the production of PIP3. This recruits PKB/Akt to the membrane where it is 
phosphorylated on Thr308 within the catalytic domain by PDK-1 and on Ser473 within the regulatory domain by an ill-defined mechanism, 
possibly involving (a) auto-phosphorylation, (b) PDK-1, (c) ILK, or (d) an unidentified PDK-2. PKB/Akt is then released from the 
membrane and translocates to other sub-cellular compartments (Adaptation from Nicholson and Anderson, 2002). 
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Although phosphorylation of Thr308 partially activates Akt (Alessi et al. 1996), 
phosphorylation of the Ser473 in a C-terminal regulatory domain is required in 
order to induce full activation of Akt (Andjelkovic et al. 1999; Scheid et al. 
2002). Many stimuli have been identified that are capable of activating Akt in 
different organs and tissues. These stimuli include insulin, IGF-1, 
ischaemia/reperfusion (hypoxia), pressure overload and β-adrenergic 
receptor agonist for example in the prevention of apoptosis in rat neonatal 
cardiomyocytes (Matsui et al. 1999; Aikawa et al. 2000; Chesley et al. 2000) 
and in ischaemia/reperfusion injury (Yamashita et al. 2001; Gao et al. 2002). 
 
In ischaemia/reperfusion models, many downstream targets of PKB/Akt exist 
but the most relevant to cardioprotection and widely investigated are those 
implicated in anti-apoptotic effects, cell growth, cardiac function, and protein 
synthesis. 
 
Protein kinase B/Akt and apoptosis 
In cardiomyocytes, insulin activates PI3-K and PKB/Akt. Activation of PI3-K 
appears largely necessary for the anti-apoptotic effects of IGF-I (Matsui et al. 
1999). In many recent studies, PKB/Akt has been shown to positively mediate 
cell survival in skeletal muscle, neurons, endothelial and epithelial cells 
(Dudek et al. 1997; Fujio et al. 1999; Edwards et al. 2002; Wang et al. 2002; 
Suhara et al. 2003). 
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Activation of PKB/Akt in vivo reduces cardiomyocyte apoptosis and infarct 
size after transient ischaemia. Studies have shown that activation of PKB/Akt 
leads to phosphorylation of the pro-apoptotic Bcl-family protein Bad, that is 
involved in the anti-apoptotic signalling in many tissues (Aikawa et al. 2000; 
Matsui et al. 2001; Negoro et al. 2001). PKB/Akt has also been reported to 
mediate phosphorylation and inhibition of caspase-9 in cell models (Cardone 
et al. 1998). 
 
Some studies have shown that activation of PKB/Akt not only reduces 
cardiomyocyte death in a model of in vivo ischaemia-reperfusion but also 
substantially improves regional and overall cardiac function. The functional 
improvement observed appeared out of proportion to the survival benefit in 
both in vitro and in vivo models. Following that observation, Matsui et al. 
(2001) investigated whether PKB/Akt activation had more direct effects on 
cardiomyocyte function after transient hypoxia. They found that activation of 
PKB/Akt in cardiomyocytes in vitro dramatically protected cardiomyocytes 
from hypoxia-induced dysfunction. 
 
They assessed cardiomyocyte function by measuring the cellular contraction 
and Ca2+, handling and found that inhibition of endogenous PKB/Akt 
substantially accelerated the hypoxia-induced decline in cardiomyocyte 
function. Their results demonstrated that acute activation of PKB/Akt 
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mediates meaningful rescue in vivo and that this reflects the combined 
benefits of inhibition of apoptosis and preservation of function (Matsui et al. 
2001). These findings imply that there is a convergence of pathways 
controlling survival and function in cardiomyocytes. 
 
Phosphatidylinositol-3 kinase 
Phosphoinositide 3-kinases (PI3-Ks) are a unique family of enzymes that 
contain both lipid and protein kinase activity (Dhand et al. 1994). This family 
of protein and lipid kinases is involved in multiple biological processes 
including cell proliferation and survival, cytoskeletal remodelling and 
membrane trafficking (Cantley 2002). 
 
PI3-K is a heterodimeric protein consisting of an 85-kDa regulatory subunit 
and a 110-kDa catalytic subunit (Kitamura et al. 1998). PI3-K is implicated in 
various metabolic effects of insulin. Recent studies have shown that insulin 
improves post-ischaemic recovery of function through PI3-K in isolated rat 
heart and that PI3-K is implicated in the regulation of PKB/Akt since inhibition 
of PI3-K by wortmannin affects PKB/Akt (Franke et al. 1995; Kohn et al. 1995; 
Louw 2001; Van Rooyen et al. 2002). 
 
Based on their biochemical properties, these enzymes are divided into three 
classes. At least three members (α, β and γ) of class I PI3-Ks are expressed 
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in the mammalian heart (Prasad et al. 2003). While PI3-Kα and β (class IA 
PI3-Ks) associate with p85-like regulatory proteins docking to phosphorylated 
tyrosines in YXXM motives, PI3-Kγ (the unique class IB PI3-K) binds directly 
or in association with the p110 adaptor to the βγ subunits of G proteins and is 
thus activated by G-protein-coupled receptors (GPCRs) (Vanhaesebroeck et 
al. 2001). 
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Table 1: Regulation of cardiac function upon modulation of PI3-K and its 
immediate effectors (Modification from Prasad et al. 2003). 
 
Molecule 
modulated Effect Reference: 
Constitutively active 
PKB/Akt 
Increased heart size 
and contractility 
Shioi et al. 
2002, 
Condorelli et 
al. 2002 
PI3-Kγ knockout 
Enhanced 
contractility, PLB 
phosphorylation, 
and cAMP 
generation 
Crackower 
et al. 2002. 
 
In vivo 
studies 
Conditional PTEN 
knockout 
 
Spontaneous 
hypertrophy and 
reduced contractility 
Crackower 
et al. 2002. 
 
 
Inhibition of PI3-K 
with inhibitors 
Increased PLB 
phosphorylation and 
myocyte contractility 
Jo et al. 
2002. 
 In vitro 
studies Disruption of PI3-K–
β-ARK interaction 
Attenuation in β-AR 
internalization 
Naga 
Prasad et al. 
2002. 
 
β-ARK, β-adrenergic receptor kinase; cAMP, cyclic adenosine monophosphate; PI3-K, 
phosphatidylinositol 3-kinase; PKB/Akt, protein kinase B (also known as Akt); PLB, 
phospholamban; PTEN, phosphatase and tensin homolog deleted on chromosome 10.  
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PI3-K and cardiac contractility 
Stimulation of β-adrenergic receptors (β-AR) leads to dissociation of 
heterotrimeric G protein into Gα and Gβγ subunits, allowing Gα to activate 
adenyl cyclase (AC) and increase intracellular cyclic adenosine 
monophosphate (cAMP) levels. Increased cAMP activates protein kinase A 
(PKA), which phosphorylates troponin I, the L-type Ca2+-channel, and 
phospholamban (PLB), leading to enhanced contractility. This is represented 
by the classic paradigm of contractility regulated by the adrenergic agonists. 
(See Fig. 2.3, p45). 
 
A study by Jo et al. (2002) has shown potentiating effects in the contractile 
and relaxant responses of adult ventricular rat myocytes to adrenergic 
stimulation in the presence of the selective PI3-K inhibitors LY294002 and 
wortmannin. The potentiating effects of PI3-K inhibitors in the myocytes were 
not accompanied by an increase in β-AR-induced cAMP levels, but were 
associated with increased PLB phosphorylation. 
 
This study suggests that PI3-K plays a role in regulating contractility of 
cardiomyocytes, possibly by either directly or indirectly modulating PLB 
phosphorylation. Furthermore, the potentiating effects of PI3-K inhibitors on 
contractile and relaxation events of myocytes were completely abolished 
upon inhibition of Gβi signalling by pertussis toxin, suggesting the involvement 
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of Gβi-mediated signalling in the regulation of PI3-K activity (Jo et al. 2002; 
Prasad et al. 2003). 
 
PI3-K and β-adrenergic signalling 
¾ Receptor function 
Adrenergic and muscarinic cholinergic receptor systems are important for the 
heart because they function in homeostatic regulation of the cardiovascular 
system. At least nine subtypes of adrenergic receptors (ARs) have been 
cloned, and of them, beta-ARs (β-ARs) are the most predominant subtypes 
present in the heart. 
 
β-ARs are further divided into three isoforms designated β1-, β2-, and β3-ARs. 
The β-AR signal system is one of the most powerful regulators of cardiac 
function, mediated by the effects of sympathetic transmitters. Failing human 
hearts are exposed to increased circulating levels of catecholamines, with 
consequent marked abnormalities in the β-AR signalling system (Rockman et 
al. 2002). 
 
Chronic increase in catecholamines leads to both β-AR desensitisation and 
down regulation (diminished receptor number) that is, in part, attributed to 
increased levels of myocardial beta-adrenergic receptor kinase – 1 (β-ARK1 ) 
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(Koch et al. 2000). β-ARK1 activation and its association with the plasma 
membrane are facilitated by binding to the liberated Gβγ subunits of the 
heterotrimeric G protein (Pitcher et al. 1998). Activated β-ARK1 
phosphorylates the β-AR, allowing for β arrestin to bind and interdict further 
coupling. The phosphorylated receptor binds β arrestin, leading to the 
recruitment of adaptor protein (AP)-2 and clathrin, which forms the clathrin-
coated endocytic vesicles and promotes receptor internalisation (Perry & 
Lefkowitz 2002; Claing et al. 2002). In one of their previous studies, Naga 
Prasad et al. (2002) showed an important link between activation of PI3-K 
and GPCRs function specifically in the process of internalisation. 
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Figure 2.3: Potential regulation of molecules by PI3-K. 
 
Agonist binding to β-ARs leads to the dissociation of heterotrimeric G proteins into Gα and Gβγ subunits. 
Gα activates AC generating cAMP, which increases the level of cardiac contractility. Absence of PI3-Kγ 
leads to enhanced contractility and cAMP generation, suggesting that PI3-K negatively (-) regulates AC. 
 
The release of Gβγ subunits activates and translocates β-ARK1 to the agonist-occupied receptor 
complex. The interaction of β-ARK1 and PI3-K to form a cytosolic complex is independent of the PI3-K 
isoform, because the binding motif is conserved in all PI3-K isoforms. β-ARK1 will complex with either 
PI3-Kα or PI3-Kγ, depending on the availability of the isoform in a given tissue, the predominant isoforms 
in heart tissues being PI3-Kα and γ, with very little expression of PI3-Kβ isoform. 
 
Upon agonist stimulation, β-ARK1 mediates translocation of PI3-K to the receptor complex. At the 
receptor complex, PI3-K generates D-3 phosphoinositides that regulate receptor internalization through 
the recruitment of essential adaptor proteins. Pharmacologic inhibition of PI3-K shows enhanced PLB 
phosphorylation, suggesting a negative regulation of PLB by PI3-K. Activation of growth factor receptors 
leads to activation of PI3-Kα, PKB/Akt, and p70S6K, which together modulate the increase in 
cardiomyocyte size (Reproduced from Naga Prasad et al., 2003). 
 
(-) 
(-) 
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¾ Evidence that some isoforms of PI3-K gamma may play an anti-
inotropic role 
The molecular details underlying the mechanism of action of PI3-Kγ in 
cardiac cells remain to be defined. However, PI3-Kγ-deficient cardiomyocytes 
showed basal alterations in the signalling events classically involved in the 
control of contractility. This process, known as modulation of cardiac 
inotropism, involves the activation by GPCRs of heterotrimeric G-proteins, the 
induction of cAMP synthesis and the subsequent activation of PKA. 
 
PKA, in turn, phosphorylates L-type Ca2+ channels, enhancing the 
transmembrane Ca2+ current that activates troponin C and the contractile 
machinery. At the same time, PKA inhibits PLB, leading to 
sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) activity and the re-
uptake of Ca2+ into the intracellular stores (Rockman et al. 2002). An 
increased concentration of cAMP both under basal conditions and after 
stimulation of β-ARs was shown in isolated mutant cardiomyocytes, where an 
increased contractility (and relaxation) was detected in PI3-Kγ-null hearts. β-
ARs are the primary players in the positive modulation of cardiac inotropism 
(Alloatti et al. 2003). A possible cause of the increased concentration of 
cAMP after β-adrenergic stimulation could be that the lack of PI3-Kγ 
promoted an abnormal elevation in the number of active β-ARs. PI3-Kγ 
appears to be involved in β-AR internalisation (Rockman et al. 2002). 
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In vitro studies showed that the phosphoinositide kinase homology domain of 
PI3-Kγ interacts with β-AR kinase 1, forming a cytosolic complex that is 
translocated to the plasma membrane upon β-AR stimulation. This event 
causes the activation of PI3-Kγ , which then facilitates the recruitment of the 
clathrin adaptor AP-2 to the desensitized receptor (Naga Prasad et al. 2000; 
Naga Prasad et al. 2002). This process, however, appears to play a minor 
role in vivo. 
 
The mammalian β-ARs comprise at least three different isoforms. Although 
the β1-AR isoform couples only to Gαs-containing G-proteins and is the major 
isoform responsible for the enhancement of the intracellular cAMP 
concentration, the β2-AR isoform can bind both Gαs and Gαi G-proteins 
(Rockman et al. 2002). In addition, in the mouse heart, β2-AR causes 
localised increases in the cAMP concentration and does not induce a positive 
inotropic response, thus suggesting that the receptor is physically restrained 
in its interactions with the activating downstream signalling machinery (Xiao 
et al. 1999). In PI3-Kγ–deficient cardiomyocytes, in contrast with the possible 
confinement of the receptor, specific stimulation of β2-ARs caused a strong 
global enhancement of cyclic adenosine monophosphate (cAMP) production, 
indicating that PI3-Kγ activity was required to maintain the β2-AR in its 
uncoupled state.  
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In agreement with this view, treatment of cardiomyocytes with PI3-K inhibitors 
such as wortmannin has been shown to enhance both β2-AR-dependent L-
type Ca2+ flux and cell shortening (Koss & Kranias 1996). These findings thus 
imply that PI3-K products might be needed to compartmentalise specific 
receptor-mediated signalling events, and that, in this specific case, they might 
prevent β-ARs from activating Gαs. 
 
Although this hypothesis is promising, several aspects of PI3-Kγ function in 
the modulation of cAMP metabolism are still far from being elucidated. For 
example, the finding that PI3-Kγ-null cardiomyocytes show increased basal 
levels of cAMP and enhanced levels of contractility even in the absence of β-
adrenergic stimulation requires comprehensive investigation. 
 
Cyclic nucleotides 
Regulation of cardiac contractility occurs primarily by either an increase in the 
concentration of activating Ca2+ ions or an alteration in the response of the 
contractile proteins to a given Ca2+ concentration (McClellan et al. 1993). 
 
Cyclic guanosine monophosphate (cGMP) is the nitric oxide (NO) second 
messenger and it has been shown that cGMP decreases relative myofilament 
response to calcium (Ca2+) and therefore enhances myocardial relaxation and 
reduces diastolic tone. Several studies have demonstrated a dissociation 
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between cGMP concentrations and contractile state, because low 
concentration of acetylcholine induced a negative inotropic effect even in the 
absence of any change in cGMP concentration (Vila-Petroff et al. 1999). 
 
Cyclic adenosine monophosphate (cAMP) is the second messenger hormone 
of β-adrenergic signalling in the heart and it mediates the inotropic effects of 
β-adrenergic agonists in cardiac myocytes (Belhassen et al. 1996). It is 
generated from adenosine trisphosphate (ATP) by the action of adenyl 
cyclase (AC).  
 
Most β-ARs, like the β1 receptor, are coupled to Gαs, which increases heart 
rate and contractility through the activation of AC and the production of 
cAMP. The increased intracellular concentration of cAMP activates protein 
kinase A (PKA), which phosphorylates troponin I, the L-type Ca2+-channel 
and PLB. These processes can be opposed by the anti-adrenergic effect of 
the M2 muscarinic receptor, which couples to Gαi and thus promotes a 
decrease of intracellular cAMP. 
 
Nitric oxide 
Nitric oxide (NO) is a free radical gas which plays a role in signal transduction 
in diverse processes. NO is synthesised from L-arginine, in a NADPH-
dependent reaction, by nitric oxide synthase (NOS). NOS has many 
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isozymes: The neuronal and endothelial NOS that are calcium dependent 
enzymes; the smooth muscle NOS and macrophages NOS that are activated 
by various cytokines and are calcium-independent, the brain NOS that is 
stimulated by the activation of ionotropic glutamate receptors such as N-
methyl-D-asparate (NMDA) receptors and non NMDA receptors  or 
metabotropic glutamate receptors (Garthwaite et al. 1988; Moncada et al. 
1989; Bredt & Snyder 1989; Ignarro 1990; Garthwaite 1991; Bredt & Snyder 
1992; Okada 1992; Yamada & Nabeshima 1997a; Yamada & Nabeshima 
1997b; Zou et al. 1998). 
 
NO was identified in the 1970s as an endothelial vasorelaxing factor and as 
such, is an important indirect regulator of cardiac function, for example 
through its modulation of coronary reserve. Recent research on cardiac NO 
has focused on its direct modulation of myocardial contractility (Massion et al. 
2003). 
 
Nitric oxide synthase expression 
In normal heart extracts, the neuronal isoform of nitric oxide synthase (nNOS) 
is thought to be localised in the sarcoplasmic reticulum, as suggested by its 
co-immunoprecipitation with the cardiac ryanodine receptor (RyR2), whereas 
nNOS-α is expressed in mitochondria (Elfering et al. 2002). In addition, both 
adrenergic and cholinergic nervous fibres express the nNOS, and eNOS is 
 55 
richly represented in endothelial and endocardial cells. Finally, the calcium-
independent NOS (inducible nitric oxide synthase, or iNOS, encoded by 
NOS2) is induced in cardiomyocytes and inflammatory cells infiltrating the 
myocardium in response to inflammatory cytokines under stress conditions 
(ischaemia) (Jung et al. 2000). 
 
Nitric oxide and cardiac function 
Nitric oxide (NO) has been implicated as a mediator of many cellular 
processes, including endothelium-dependent relaxation of blood vessels, 
chemical communication between peripheral nerves and smooth muscles and 
inhibition of platelet aggregation. The major quantity of the endogenous 
physiological NO in the heart is produced by the coronary endothelium, but NO 
can also be produced within the cardiac myocytes themselves by the 
constitutive NO synthase NOS-3. NO influences many major facets of cardiac 
myocyte function, including signal transduction, Ca2+ cycling, and mitochondrial 
respiration (Vila-Petroff et al. 1999). 
 
Spatial confinement of NOS isoforms plays a central role in regulating cardiac 
contractile function. Recent studies have shown that nNOS (the neuronal 
isoform of NOS) influences the frequency-mediated rise in cardiac contractility 
and calcium cycling in a manner previously thought to be specific to eNOS. 
The intracellular mechanisms accounting for the inotropic effects of NO are 
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diverse (Balligand & Cannon 1997; Balligand 1999). With exogenous NO, 
several of these intracellular mechanisms were found to operate in a 
concentration-dependent bimodal fashion, resulting in inotropically inverse 
effects at higher NO exposure (Brunner et al. 2001). These effects are 
mediated principally through cGMP-related mechanisms, specifically via the 
reduction of Ca2+ influx through L-type Ca2+ channels – either through 
activation of cGMP-dependent phosphodiesterase or cGMP-dependent protein 
kinase (PKG) (Belhassen et al. 1996; Vila-Petroff et al. 1999). 
 
In recent research, one group found that nNOS knockout (nNOS-/-) mice 
have an attenuated positive force-frequency response in conjunction with 
impaired increase in SR calcium load (Khan et al. 2003), consistent with a 
facilitatory effect of nNOS on SERCA activity. In contrast, another group 
found that there was an increased SR calcium load in myocytes from nNOS-/- 
mice that was attributed to a compensatory increase in trans-sarcolemmal 
calcium entry in the hearts (Sears et al. 2003). 
 
In normal hearts, the tonic release of NO directly influences several 
components of cardiac function. Acute inhibition of NOS decreases 
contractile force in isolated rat hearts, induces regional wall thickening in pigs, 
left ventricular diameter shortening and stroke work in dogs (Puybasset et al. 
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1996; Kojda et al. 1997; Heusch et al. 2000; Cotton et al. 2001; Recchia et al. 
2002). 
 
Nitric oxide regulation of diastolic and systolic cardiac properties in 
normal mammalian heart 
Non-specific inhibition of NOS or genetic deletion of eNOS and iNOS has little 
effect on the basal contractile function in the mammalian heart and in isolated 
cardiomyocytes (Massion et al. 2003). The neuronal NOS is a possible 
exception since its acute inhibition or chronic genetic ablation resulted in an 
increase in L-type calcium current and amplitude of contractile shortening in 
isolated mouse cardiomyocytes (at low catecholamine concentrations), as 
well as contractility in vivo (Ashley et al. 2002). Inhibition or genetic ablation 
of nNOS resulted in a slowing of calcium transient decay and myocyte re-
lengthening in one study (Sears et al. 2003), and in an unaffected basal 
relaxation in vivo in another (Khan et al. 2003); however, the higher heart rate 
of nNOS-/- mice may confound the interpretation of their tau values, i.e., had 
they been corrected for heart rate, tau values of nNOS-/- may have unveiled 
an impaired relaxation compared with wild type (WT), compatible with the first 
study. These results can represent a possible effect of nNOS on calcium re-
uptake into the sarcoplasmic reticulum (SR). 
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In isolated hearts, NOS inhibition elevates left ventricular end-diastolic 
pressure (LVEDP) and decreases the preload-recruitable rise in cardiac 
output (Prendergast et al. 1997). Endothelial NOS (eNOS) activation appears 
to play a major role in insulin-mediated mitigation of cardiomyocyte apoptosis 
as well as infarct size in a rat model of ischaemia-reperfusion injury (Gao et 
al. 2002). NO plays a key role in cardioprotective effects of acute 
corticosteroid therapy during ischaemia-reperfusion injury (Hafezi-Moghadam 
et al. 2002). This study has also shown that the PI3-K/Akt signalling pathway 
tightly regulates activation of eNOS in ischaemia-reperfusion injury  
 
Nitric oxide regulation of diastolic and systolic cardiac properties in 
diseased and in normal mammalian heart. 
In the basal state, the effect of NO is bimodal, with a positive inotropic effect 
at low concentrations of NO exposure but a negative one at higher 
concentrations. Several studies also found no effect at all of either exogenous 
or endogenous NO. It is difficult to define the meaning of low or high 
concentrations of NO since there is no standardised protocol set when it 
comes to the concentrations of different reagents used for experiments. The 
lack of standardisation may account for the differences observed between 
studies. 
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Although iNOS and nNOS are upregulated with cardiac disease, non-specific 
NOS inhibitors have little effect on basal function and force–frequency 
relationships in heart failure (Massion et al. 2003). This is perhaps explained 
by the biodegradation of the NO produced, e.g. by myoglobin, as exemplified 
in the mild phenotype of iNOS overexpressors; however, the fact that 
myoglobin content is decreased in several cardiomyopathies suggests that 
additional factors are at play to account for the relative insensitivity of the 
failing myocardium in the face of upregulated NOS. eNOS down regulation 
may impair the Frank–Starling adaptation of the terminally failing heart, both 
through defective stretch-dependent contractile reserve and altered relaxation 
dependent on paracrine eNOS signalling (Wunderlich et al. 2003).  
 
Altered NOS expression/regulation in the diseased heart participates in 
cardiac dysfunction. During cardiac diseases, the relative abundance of each 
NOS may dramatically change, with upregulation of nNOS and iNOS, but 
down regulation of eNOS (Massion et al. 2003). Concurrent changes in the 
abundance/interaction of allosteric modulators (caveolin-3, hsp90), availability 
of cofactors, concentration of endogenous inhibitors, or biochemical 
uncoupling further affect all NOS activity.  
 
The NOS compartmentalisation is also disrupted as a consequence of cell 
ultrastructure remodelling such as loss of T-tubular structure in diseased 
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cardiomyocytes. The nature and intensity of stimuli affecting each NOS are 
profoundly modified in failing hearts, with e.g. increased circulating 
catecholamines, relative changes in beta-adrenergic isoform expression (e.g. 
upregulation of beta 3-adrenoceptors) (Moniotte et al. 2001). 
 
Beta-adrenergic response. 
In normal mammalian heart, the β-adrenergic inotropic effect can be 
modulated in a bimodal fashion, depending not only on the concentration of 
NO but also of catecholamines (Massion et al. 2003). The response to β-
adrenergic stimulation therefore depends on the concentration of NO and 
catecholamines. Ji et al (1999), in one of their studies, found that at a fixed 
concentration of NO, cardiac response to β-adrenergic stimulation was 
increased at low catecholamine levels but decreased at high levels (Ji et al. 
1999). 
 
In contrast, a NO-dependent attenuation of the beta-adrenergic response is 
observed in isolated cardiomyocytes, whole heart or in vivo animal 
preparations and in human cardiac diseases. Originally, this was attributed to 
iNOS in cardiomyocytes (as well as infiltrating inflammatory cells) (Balligand 
et al. 1993) and was confirmed in lipopolysaccharide-induced (LPS) rat 
ventricular myocytes over-expressing iNOS and in patients with heart failure  
and iNOS over-expression (Ziolo et al. 2001; Ziolo et al. 2003). 
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The mammalian heart is characterised by the expression of all three isoforms 
of NOS in various cell types of the myocardium, including cardiac myocytes 
themselves. Their sub-cellular compartmentalisation ensures specific NO 
signalling to co-localised effectors in response to physical (e.g. stretch) or 
receptor-mediated stimuli. eNOS and nNOS cooperatively sustain normal 
excitation contraction coupling and contribute to the early and late phases of 
the Frank–Starling mechanism of the heart. In addition, they attenuate the 
β1/β2-adrenergic increase in inotropy and chronotropy, and reinforce the (pre- 
and post-synaptic) vagal control of cardiac contraction, thereby preventing 
excessive stimulation by catecholamines. 
 
In the ischaemic and failing myocardium, eNOS coupled to overexpressed β-
3-adrenoceptors further contributes to the attenuation of the inotropic effect of 
catecholamines, as does iNOS. nNOS expression also increases in the aging 
and ischaemic heart, but its role remains to be defined (Ziolo & Bers 2003) 
 
In addition, Gao et al. (2002) showed that eNOS is a substrate for PKB/Akt 
and that phosphorylation of eNOS by PKB/Akt results in a calcium-
independent NO production. In their study, treatment of hearts with insulin 
resulted in an increased eNOS phosphorylation and an increased production 
of NO. When the hearts where treated with wortmannin in the presence of 
insulin, they observed that eNOS phosphorylation was completely blocked 
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and the increase of NO production induced by insulin was abolished. When 
they treated the hearts with L-NAME, there was no effect on eNOS 
phosphorylation but NO production was reduced in insulin treated hearts.  
These results led them to the conclusion that, treatment of myocardial tissue 
in the ischaemia/reperfusion model with insulin activates eNOS and increases 
NO production through the PI3-K – PKB/Akt pathway. 
 
From the available literature it can be observed that insulin-induced 
improvements in cardiac functions are widely investigated in models of 
ischaemia and reperfusion. However, little data exists on the effects of insulin 
on the heart under normoxic condition. We therefore hypothesize that insulin 
may improve cardiac function under normoxic conditions and we believe that 
an investigation into the effects of insulin on cardiac function and pathways 
involved under normoxic conditions may help us to better understand the 
mechanisms of insulin-induced cardioprotection. Therefore, in the present 
study, we will first determine a suitable dose of insulin at which a positive 
inotropic response could be detectable under normoxic conditions. This will 
be achieved by perfusing the hearts with three different concentrations of 
insulin. We will then investigate the possible mechanisms involved in insulin-
induced increases in contractility with specific reference to the vasculature 
and the coronary flow and we will end the present work with a preliminary 
protocol on the investigation of a possible involvement of PI3-K and its 
 63 
downstream effectors on the insulin effects on cardiac functions under 
normoxic conditions. 
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Figure 2.4: Proposed summary of PI3-K, PKB/Akt and NO signalling involved in the increased contractility in the heart.  
β-AR receptor stimulation produces a positive inotropic effect through activation of AC leading to increases in intracellular cyclic AMP levels. 
Subsequent activation of cAMP-dependent protein kinase (PKA) leads to downstream phosphorylation of target proteins, including the L-type 
calcium channel to increase trans-sarcolemmal calcium influx and sarcoplasmic reticulum calcium uptake. 
 
GF, Insulin, IGF-1 β-AR 
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CHAPTER 3 
 
MATERIALS AND METHODS 
 
EXPERIMENTAL ANIMALS 
Male Wistar rats (280–340g) were supplied by the Department of Physiological 
Sciences Animal Unit at the University of Stellenbosch. The rats were allowed 
free access to food (standard rat chow) and water. They were maintained in the 
animal house at a constant temperature of 21ºC and were exposed to a twelve-
twelve hour light-dark cycle. 
 
DRUGS AND CHEMICALS 
Drugs and chemicals used were obtained from the following sources: 
 
Amersham Bioscience: 
Anti-rabbit IgG, horseradish peroxidase-labelled secondary antibody, Hyperfilm, 
Enhanced chemiluminesence detection kit (RPN 2103) 
 
Cell Signalling Technology: 
Anti-Akt antibody, anti-PI3K-p110α antibody, anti-phospho-Akt-Thr (308) 
antibody, anti-phospho-Akt-Ser (473) antibody 
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Eli Lilly SA (Fegersheim, France): 
Humulin N insulin 
 
Millipore: 
PVDF membrane 
 
Sigma Chemicals Company (South Africa): 
Bovine Serum Albumin, Bromophenol blue, Gel loading buffer, Lysis buffer,  
N-ωnitro-L-Arginine methyl ester (L-NAME), Wortmannin, 
 
All other reagents were of analytical grade, and were supplied by Merck, Fluka 
and Sigma Chemical Company (South Africa) 
 
PHYSIOLOGICAL SALT SOLUTION 
Krebs-Henseleit (KH) solution containing in mM, 119 NaCl, 25 NaHCO3, 1.2 
KH2PO4, 4.7 KCl, 0.59 MgSO4-7H2O, 1.25 CaCl2-2H2O and 5 mM of glucose and 
gassed with 95% O2 and 5% CO2 at pH 7.4 was used. 
 
INHIBITORS 
L-NAME was freshly made before each perfusion and was dissolve in KH solution 
for a 10μM concentration and aliquots were kept at 4°C until used. 
Wortmannin was dissolved in DMSO and aliquots of 2mM were stored a -40°C 
until used. 
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All other compounds were dissolved in sterile saline unless otherwise stated. 
 
ETHICAL CLEARANCE 
Ethical clearance for this study was granted by Sub-committee C of the University 
of Stellenbosch. 
 
MEASURED VARIABLES 
In order to compare the function of the hearts in the different groups, heart rate 
(HR, bpm), systolic pressure (SP, mmHg), diastolic pressure (DP, mmHg) and 
the temperature (oC) were measured every 5 minutes from the starting of the 
experiment until the end of experiment. Coronary flow (CF, ml/min) was 
measured, by manually collecting the volume of heart’s effluent during one 
minute time period, 5 minutes after starting the experiment and every 5 min until 
the end of perfusion. The left ventricular developed pressure (LVDevP) was 
calculated as the difference between the SP and the DP. 
 
EXCLUSION CRITERIA 
Rats with body mass outside of the range of 280 – 340 g were not used for the 
experiments. Hearts were excluded from the study if the following were not met 
during the stabilisation period: 
• coronary flow of 10 – 16 ml/min 
• heart rate of 210 – 350 beats per minute  
• left ventricular developed pressure of 70 – 150 mmHg  
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PERFUSION PROTOCOL: ISOLATED PERFUSED RAT HEART 
Male Wistar rats (280–340 g) were anaesthetised with thiopentone sodium (120 
mg/kg ip). Following cervical dislocation the chest was opened and the heart 
excised. The hearts were arrested in ice cold KH buffer (4ºC). Within 60 
seconds of excising the heart the aorta was cannulated with a stainless steel 
cannula and perfused with KH on a Langendorff perfusion system. Hearts were 
retrogradely perfused at a constant pressure of 100 cm H2O. The left atrium and 
the non-cardiac tissues were removed from the hearts. Temperature was 
maintained at a constant 37°C by means of a circulating water bath and a water-
jacketed glass reservoir. The HR, the DP and SP were recorded via a pressure 
transducer and data acquisition system (ADInstrument Powerlab 200) 
connected to the heart via a water filled balloon inserted into the left ventricle. 
The contraction force of the heart against the balloon caused water 
displacement giving us an indication of pressure. Coronary flow was obtained 
manually by collecting heart effluent for one minute with a graduated 
measurement cylinder. The myocardial temperature was monitored with a 
thermocouple temperature probe inserted into the right coronary sinus. 
 
PRELIMINARY STUDY - INSULIN EFFECT ON CARDIAC FUNCTION 
The initial protocol was designed to investigate a suitable dose of insulin at 
which an effect of insulin on heart function during normal perfusion could be 
detected. Three doses of insulin, ranging from the physiological to the 
pathophysiological were used. The three different concentrations of insulin were: 
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0.3 mIU/mL (Ins3), 0.6 mIU/mL (Ins6) and 1.0 mIU/mL (Ins10). Hearts were 
perfused with KH buffer during the stabilisation period and with the different 
concentrations of insulin for the remainder of the experimental protocol, except 
for the control group that received only KH throughout the experiment. All the 
hearts were allowed 10 minutes stabilisation time before experimental protocol 
began.  
 
The groups were divided as follows:  
Group 1a: Control; KH-buffer (Gluc5) 
Group 1b: KH-buffer + insulin 0.3 mIU/mL (Ins3) 
Group 1c: KH-buffer + insulin 0.6 mIU/mL (Ins6) 
Group 1d: KH-buffer + insulin 1.0 mIU/mL (Ins10) 
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Insulin 0.3mIU/ml
Control
KH Buffer
Insulin 0.6mIU/ml
Insulin 1.0mIU/ml
Ins0.3
Ins0.6
Ins1.0
Stab
-10 min 0 min 10 min 20 min 30 min
Addition of different drugs
0 min 10 min 40 min
 
Figure 3.1: Perfusion protocol for insulin dose response 
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INHIBITOR STUDIES 
To investigate the signalling pathways involved in the inotropic effect of insulin 
on the heart, inhibitors of two specific pathways were added to KH-buffer in the 
presence of insulin. The first, L-NAME, an inhibitor of nitric oxide synthase 
(NOS), was used to investigate the involvement of nitric oxide (NO). Secondly, 
Wortmannin, an inhibitor of phosphatidylinositol 3-kinase (PI3-K), was used for 
the investigation of the role of PI3-K in the responses seen. 
 
For the purpose of further biochemical analysis, hearts were freeze-clamped at 
10, 20, and 30 minutes of experimental time as well as at the end of the 
stabilisation period with Wollenberger tongs. The Wollenberger tongs were pre-
cooled in liquid nitrogen. The freeze-clamped hearts were then stored at -80 ºC 
until analysed. 
 
ROLE OF NITRIC OXIDE IN THE RESPONSES TO INSULIN 
This protocol was designed to investigate the involvement of nitric oxide in the 
effects of insulin on heart, by inhibiting nitric oxide synthase (NOS). L-NAME, a 
non specific inhibitor of NOS, was used in conjunction with insulin in KH-buffer.  
As for the insulin protocol, hearts in this group were perfused with Krebs-
Henseleit buffer during the stabilisation period and with insulin alone or insulin 
and L-NAME. The control group received only KH throughout the experiment. 
The dose of 0.3 mUI/mL of insulin was chosen from the previous protocol and 
was used for all subsequent protocols where insulin was involved. In the present 
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protocol, we used KH + insulin throughout the experimental time after the 10 
minutes stabilisation. In the last group, L-NAME was administered for 10 
minutes in association with insulin immediately after the stabilisation time. After 
L-NAME administration, hearts received insulin until the end of the experiment.  
The perfusion protocol for perfusion with L-NAME is represented in figure 3.2. 
 
The groups were divided as follows: 
Group 2a: Control: KH-buffer 
Group 2b: KH-buffer + insulin 0.3 mIU/mL  
Group 2c: KH-buffer + insulin 0.3 mIU/mL + L-NAME 10 μM 
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Control
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Stab
0 min 10 min 40 min
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Figure 3.2: Perfusion protocol with L-NAME 
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ROLE OF PI3-K IN THE RESPONSES TO INSULIN 
The setting up of the present protocol aimed to investigate the role of PI3-K in 
the inotropic effects of insulin in normal hearts. Hearts in this group were 
perfused with Krebs-Henseleit buffer during the stabilisation period and with 
insulin alone or insulin and wortmannin. The control group received only KH 
throughout the experiment. We used KH + insulin throughout the experimental 
time after the 10 minutes stabilisation. Wortmannin was administered in 
conjunction with insulin throughout the experiment after the stabilisation period 
for the last group of the present protocol.  
 
The perfusion protocol for perfusion with wortmannin is represented in figure 3.3. 
 
The groups were divided as follows: 
Group 3a: Control: KH-buffer 
Group 3b: KH-buffer + insulin 0.3 mIU/mL  
Group 3c: KH-buffer + insulin 0.3 mIU/mL + wortmannin 100 nM 
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Control
KH Buffer
FC FC FC FC
Insulin 0.3mIU/ml
FC FC FC
Insulin 0.3mIU/ml + Wortmannin 100nm
Wort
FC FC FC
Stab
-10 min 0 min 10 min 20 min 30 min
Stab
0 min 10 min 40 min
Addition of different drugs
 
Figure 3.3: Perfusion protocol with wortmannin 
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MEASUREMENT OF PKB/Akt PHOSPHORYLATION AND PI3-K 
The freeze-clamped heart tissue samples stored at – 80oC were used following 
freeze-drying for 24h. The freeze dried tissue was reduced to powder and 
homogenised with a 1:1 w/v lysis buffer for 10 seconds. The homogenates were 
then centrifuged (2500 xg, 10 min, 4oC) to remove particulate matter. The protein 
concentration in the supernatants was determined by the Bradford dye-binding 
assay using bovine serum albumin (BSA) as a standard (Bradford, 1976).  
 
The lysates were diluted in Laemmli sample buffer, boiled for 5 min. 40 μg protein 
was separated using sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE) on a 10% gel, on a standard Mini-PROTEAN 3 system (Bio-Rad). 
The separated proteins were transferred to a polyvinylidenedifluoride (PVDF) 
membrane. Following transfer, the membranes were stained with Ponceau S Red 
(reversible stain) to visualise the proteins, and to assess the quality and quantity 
of the transfer. Following scanning and removal of the Ponceau-S Red, non-
specific binding sites on the membranes were blocked with 5% fat-free milk in 
Tris-buffered saline containing 0.1% tween20 (0.1% TBS-T). The amounts of total 
protein as well as phosphorylation of PKB/Akt were visualized using appropriate 
antibodies. Membranes were probed with either an anti-Akt antibody (for total 
Akt), anti-phospho-Akt (Thr 308) antibody, anti-phospho-Akt (Ser 473) antibody or 
an anti-PI3K-p110 antibody. The membranes were washed with TBS-T and the 
immobilised primary antibodies were conjugated with a diluted horseradish 
peroxidase conjugated secondary antibody. After washing thoroughly with TBS-T, 
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the membranes were incubated in an enhanced chemmiluminescent detection 
reagent (ECL Plus™) for 5 mins and were quickly exposed to an autoradiography 
film. Films were subsequently scanned and the bands analysed using 
densitometry (UN-SCAN-IT, Silkscience). Protein were expressed in arbitrary 
units and all proteins were normalized to control (the value of 1 was taken as the 
total protein content of the control). 
 
STATISTICAL ANALYSIS 
Results are reported as the mean ± standard error of the mean.  Data were 
analysed by ANOVA with a Bonferroni post hoc test.  The condition of P<0.05 
was considered to be statistically significant. 
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C H A P T E R  4  
 
RESULTS 
 
FUNCTIONAL DATA - INSULIN DOSE RESPONSE 
 
EFFECTS OF INSULIN CARDIAC FUNCTION 
For the investigation of a suitable dose of insulin at which an effect on cardiac 
function could be detected, three different concentrations of insulin were used, 
namely: 0.3 mIU/mL; 0.6 mIU/mL; 1.0 mIU/mL. 
 
HEART RATE (FIGURE 4.1.A) 
At the end of the stabilisation period the heart rate (HR) for the control group (n 
= 14) was 308.7 ± 9.9 beats per minutes (bpm); 295.6 ± 9.5 bpm for the group 
treated with insulin at the concentration of 0.3 mIU/mL (Ins0.3) (n = 12), 295.0 ± 
14.7 bpm for the group treated with insulin at the concentration of 0.6 mIU/mL 
(Ins0.6) and 293.2 ± 8.7 bpm for the group treated with insulin at the 
concentration of 1.0 mIU/mL (Ins1.0) (n = 7) (See Fig. 4.1.a, p75). There was no 
significant different between the four groups. 
 
After 30 min of perfusion with either KH + glucose (Ctrl), or with KH + glucose + 
insulin at different concentrations (Ins0.3, Ins0.6 and Ins1.0), the HR value were as 
follows: 282.1 ± 11.6 bpm for the control group, 264.0 ± 7.8 bpm for Ins0.3, 267.0 
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± 13.2 bpm for Ins0.6 and 290.2 ± 8.8 bpm for Ins1.0, no significant statistical 
difference was observed (See Fig. 4.1.a, p79). 
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Figure 4.1.a: Effect of three doses of insulin on heart rate. 
 
Heart rate of hearts perfused with KH solution containing either 5 mM glucose (Control group, n 
= 14) or with 5 mM glucose and insulin at three different concentrations (0.3 mIU/mL (Ins0.3) n = 
12, 0.6 mIU/mL (Ins0.6) n = 8, and 1.0 mIU/mL (Ins1.0) n = 7). 
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LEFT VENTRICULAR DEVELOPED PRESSURE (FIGURE 4.1.B) 
Left ventricular developed pressure (LVDevP) of the isolated perfused hearts at 
the end of the stabilisation time was 78.0 ± 3.8 mmHg for the control group (n = 
14), 71.08 ± 2.5 mmHg for Ins0.3 (n = 12), 80.40 ± 4.3 mmHg for Ins0.6 (n = 8) 
and 74.91 ± 2.9 mmHg for Ins1.0 (n = 7). Thirty minutes after the experiment, the 
LVDevP was 79.7 ± 3.3 mmHg for the control group, 95.66 ± 4.1 mmHg for the 
Ins0.3 group, 90.32 ± 5.6 mmHg for the Ins0.6 group, and 92.38 ± 6.2 mmHg for 
the Ins1.0 group. Hearts perfused with Ins0.3 showed a linear increase from the 
start of the perfusion until 15 min of perfusion. Then the increase slowed down 
until the end of the experiment. No significant differences were detected within 
the groups where insulin was administered. Significant difference was observed 
between the control group and the insulin group at the concentration of 0.3 
mIU/mL from the 25th min until the end, p<0.05 (See Fig. 4.1.b, p80). 
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Figure 4.1.b: Effect of three doses of insulin on LVDevP 
 
LVDevP of hearts perfused with KH solution containing either 5 mM glucose (Control group, n = 
14) or with 5 mM glucose and insulin at three different concentrations (0.3 mIU/mL (Ins0.3) n = 
12, 0.6 mIU/mL (Ins0.6) n= 8, and 1.0 mIU/mL (Ins1.0) n= 7), # p<0.05 
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CORONARY FLOW (FIGURE 4.1.C) 
The coronary flow (CF) of the group that received the high concentration of 
insulin seemed to be slightly higher than all other groups, but there was no 
statistically significant difference between all groups. At the end of the 
stabilisation period the coronary flow was 13.3 ± 0.4 ml/min for the control group 
(n = 14), 13.46 ± 0.6 ml/min for the Ins0.3 group (n = 12), 15.3 ± 0.9 ml/min for 
the Ins0.6 group (n = 8), and 14.54 ± 0.7 for Ins1.0 group (n = 7). At the end of the 
experiment, the CF values were 11.9 ± 0.5 ml/min, 12.93 ± 0.5 ml/min, 13.4 ± 
0.6 ml/min, and 13.71 ± 0.8 ml/min for the control group, the Ins0.3 group, the 
Ins0.6 group, and the Ins1.0 group respectively (See Fig.4.1.c, p82). 
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Figure 4.1.c: Effect of three doses of insulin on coronary flow 
 
CFof hearts perfused with KH solution containing either 5 mM glucose (Control group, n = 14) or 
with 5 mM glucose and insulin at three different concentrations (0.3 mIU/mL (Ins0.3) n = 12, 0.6 
mIU/mL (Ins0.6) n = 8, and 1.0 mIU/mL (Ins1.0) n = 7). 
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EFFECTS OF SPECIFIC PATHWAY INHIBITORS ON CARDIAC FUNCTION 
To investigate the role of the nitric oxide pathway in the inotropic response to 
insulin seen in the heart we used 10 μM of L-NAME (Du Toit E.F., 1998), a non-
specific inhibitor of nitric oxide synthase, for the implication of nitric oxide in the 
effect of insulin on the vasculature and the flow. 
 
Further to this, in a preliminary study we investigated the role of the PI3-K 
pathway in the inotropic effect of insulin under normoxic conditions by using the 
PI3-K inhibitor wortmannin (100nm). 
 
EFFECT OF L-NAME ON HEART RATE (FIGURE 4.2.A) 
At the end of the stabilisation period, the HR’s were 293.78 ± 7.48 bpm for the 
control group (Ctrl) n = 25, 296.09 ± 6.65 bpm for the insulin group (Ins) 
n = 29, and 299.20 ± 9.2 bpm for the L-NAME group (LNM) n = 11. Immediately 
after L-NAME administration, heart rate dropped to 229.8 ± 10.6 bpm for the 
group that received L-NAME. Following the 20 minutes perfusion with insulin 
after administration of L-NAME, the heart rate values were 253.2 ±10.1 bpm. A 
drop in the heart rate was observed during administration of L-NAME and during 
the 10 minutes following L-NAME administration in the group that received L-
NAME. There was a significant difference between the control and the insulin 
groups compared to the group that received L-NAME, p<0.05 (See Fig. 4.2.a, 
p85). 
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Figure 4.2.a: Effects of L-NAME on heart rate of isolated perfused rat hearts 
 
Heart rate of hearts perfused with KH solution containing either 5 mM glucose (Control, n=25) or 
5 mM glucose + 0.3 mIU/mL insulin (Ins group, n=29), or with 5 mM glucose + 0.3 mIU/mL 
insulin + 10 μM L-NAME (LNM group, n=11), # p<0.05. 
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EFFECTS OF L-NAME ON LEFT VENTRICULAR DEVELOPED PRESSURE 
(FIGURE 4.2.B) 
After the stabilisation time, the LVDevP was 84.69 ± 3.38 mmHg for the control 
group (n = 25), 78.05 ± 2.87 mmHg for Ins group (n = 29), and 87.90 ± 4.73 
mmHg for LNM group (n = 11). Immediately after administration of L-NAME, 
LVDevP values were 84.16 ± 2.67 mmHg for the control group, 89.11 ± 2.74 
mmHg for the Ins group, and 69.97 ± 11.07 mmHg for LNM group. 
 
At the end of perfusion, the LVDevP values were 84.41 ± 2.96 mmHg for the 
control group, 99.23 ± 3.11 mmHg for the Ins group, and 84.16 ± 8.86 mmHg for 
the LNM group. Significant increase in LVDevP was observed in the group that 
received insulin compared to the control group. A decrease, but not significant, 
in the LVDevP was also observed during the L-NAME administration time in the 
group that received L-NAME (See Fig. 4.2.b, p87). 
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Figure 4.2.b: Effects of L-NAME on LVDevP of isolated perfused rat hearts 
 
LVDevP of hearts perfused with KH solution containing either 5 mM glucose (Control, n=25) or 5 
mM glucose + 0.3 mIU/mL insulin (Ins group, n=29), or with 5 mM glucose + 0.3 mIU/mL insulin 
+ 10 μM L-NAME (LNM group, n=11), # p<0.05. 
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EFFECT OF L-NAME ON CORONARY FLOW (FIGURE 4.2.C) 
Coronary flow at the end of the stabilisation period was 13.55 ± 0.33 ml/min for 
the control group (n = 25), 13.77 ± 0.35 ml/min for the Ins group (n =29), and 
14.33 ± 0.5 ml/min for the LNM group (n = 11). After 10 minutes of perfusion, 
there was a significant decrease of CF of the LNM group compared to Gluc5 and 
Ins groups, p<0.05. CF values 12.42 ± 0.34 ml/min for the control group, 12.81 ± 
0.33 ml/min for the Ins group, and 6.8 ± 0.9 ml/min for the LNM group. 
 
At the end of the experiment, CF was 12.50 ± 0.41 ml/min for the control group, 
12.88 ± 0.30 ml/min for the Ins group, and 8.95 ± 0.8 ml/min for the LNM group 
(See Fig. 4.2.c, p89). 
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Figure 4.2.c: Effects of L-NAME on CF of isolated perfused rat hearts 
 
CF of hearts perfused with KH solution containing either 5 mM glucose (Control, n=25) or 5 mM 
glucose + 0.3 mIU/mL insulin (Ins group, n=29), or with 5 mM glucose + 0.3 mIU/mL insulin + 10 
μM L-NAME (LNM group, n=11), # p<0.05. 
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PRELIMINARY WORTMANNIN STUDY 
It has been widely demonstrated that the cardioprotection of insulin on the 
ischaemic and reperfused isolated heart is mediated by PI3-K. To investigate 
the implication of P3-K in the inotropic effect of insulin under normoxic 
conditions, we conducted a preliminary study where we used 100 nM of 
wortmannin, a specific inhibitor of PI3-K. 
 
EFFECT OF WORTMANNIN ON HEART RATE (FIGURE 4.3.A) 
 
At the end of the stabilisation period HR of the control group (Gluc5, n = 25) was 
293.78 ± 7.48 bpm, 296.09 ± 6.65 bpm for the insulin group (Ins, n = 29), and 
297.70 ± 5.5 bpm for the wortmannin group (Wort, n = 26). At the end of the 
experiment, the heart rate values were 274.58 ± 7.69 bpm for the control, 
265.18 ± 4.94 bpm for Ins, 250.58 ± 6.9 bpm for the Wort group. A significant 
decrease in heart rate of the hearts that received insulin + wortmannin was 
observed from 10 minutes after the initiation of perfusion with wortmannin until 
the end of the perfusion protocol, p<0.05 (See Fig. 4.3.a, p 91). 
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Figure 4.3.a: Effects of wortmannin on HR of isolated perfused rat hearts 
 
HR of hearts perfused with KH solution containing either 5 mM glucose (Control, n=25) or 5 mM 
glucose + 0.3 mIU/mL insulin (Ins group, n=29), or with 5 mM glucose + 0.3 mIU/mL insulin + 
100 nM wortmannin (Wort group, n=26), # p<0.05. 
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EFFECT OF WORTMANNIN ON LEFT VENTRICULAR DEVELOPED 
PRESSURE (FIGURE 4.3.B) 
 
Left ventricular developed pressure (LVDevP) values at the end of the 
stabilisation period were 84.69 ± 3.38 mmHg for the control group (n = 25), 
78.05 ± 2.87 mmHg for the Ins group (n = 29), and 87.62 ± 3.34 mmHg for the 
Wort group (n = 26). After 30 minutes of experiment, the LVDevP was 84.41 ± 
2.96 mmHg for the control group, 99.23 ± 3.11 mmHg for the Ins group, and 
61.90 ± 4.91 mmHg for the Wort group. Significant decrease in LVDevP was 
observed in the group that received wortmannin compared to the control and to 
the insulin groups, p<0.01 (See Fig. 4.3.b, p93). 
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Figure 4.3.b: Effects of wortmannin on LVDevP of isolated perfused rat hearts 
LVDevP of hearts perfused with KH solution containing either 5 mM glucose (Control, n=25) or 5 
mM glucose + 0.3 mIU/mL insulin (Ins group, n=29), or with 5 mM glucose + 0.3 mIU/mL insulin 
+ 100 nM wortmannin (Wort group, n=26), # p<0.01. 
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EFFECT OF WORTMANNIN ON CORONARY FLOW (FIGURE 4.3C) 
Coronary flow at the end of the stabilisation period was 13.55 ± 0.33 ml/min for 
the control group (n = 25), 13.77 ± 0.35 ml/min for the Ins group (n = 29), and 
13.67 ± 0.4 ml/min for the Wort group (n = 26). 
 
At the end of the experiment, CF was 12.50 ± 0.41 ml/min for the control group, 
12.88 ± 0.30 ml/min for the Ins3 group, and 8.92 ± 0.4 ml/min for the Wort100 
group. A rapid significant decrease in the CF of hearts that received wortmannin 
was observed immediately from the administration of wortmannin at the 
beginning of the experiment, p<0.01. The low coronary flow was sustained until 
the end of the experiment time (See Fig. 4.3.c, p95). 
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Figure 4.3.c: Effects of wortmannin on CF of isolated perfused rat hearts 
CF of hearts perfused with KH solution containing either 5 mM glucose (Control, n=25) or 5 mM 
glucose + 0.3 mIU/mL insulin (Ins group, n=29), or with 5 mM glucose + 0.3 mIU/mL insulin + 
100 nM wortmannin (Wort group, n=26), # p<0.01. 
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BIOCHEMICAL ANALYSIS DATA 
EFFECT OF L-NAME ON PKB/Akt 
TOTAL PKB/Akt  
As expected, the content of total PKB/Akt of hearts in all groups was the same 
from the starting of the experiment up to the end of the experimental protocol. 
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Figure 4.4.a: Total PKB/Akt of hearts perfused standard KH solution containing: 
Ctrl (0): 5mM glucose measured immediately after stabilisation 
Ctrl (10): 5mM glucose measured 10 min after experiment starts. 
Ins (10):5mM glucose and 0.3mIU/mL insulin, measured 10 min after experiment starts. 
LNM(10): 5mM glucose + 0.3mIU/mL insulin and 10μM L-NAME measured 10 min after 
experiment starts. 
 
Total PKB/Akt was visualized with an appropriate primary antibody. n = 3 hearts per group. 
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AT 30 MIN 
 
Ctrl (0) Ctrl (30) Ins (30) LNM (30)
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Figure 4.4.b: Total PKB/Akt of hearts perfused standard KH solution containing: 
Ctrl (0): 5mM glucose measured immediately after stabilisation 
Ctrl (30): 5mM glucose measured 30 min after experiment starts. 
Ins (30):5mM glucose and 0.3mIU/mL insulin, measured 30 min after experiment starts. 
LNM (30): 5mM glucose + 0.3mIU/mL insulin and 10μM L-NAME measured 30 min after 
experiment starts. 
 
Total PKB/Akt was visualized with an appropriate primary antibody. n = 3 hearts per group. 
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EFFECT OF L-NAME ON PHOSPHORYLATED PKB/Akt THREONINE 
10 MIN 
Phosphorylation of the threonine isoform of PKB/Akt was pronounced in the 
group that received L-NAME compared to the control and the insulin group. We 
did not find any significant, difference between al the groups. 
Ctrl (0) Ctrl (10) Ins (10) LNM (10)
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Figure 4.5.a: Phosphorylated PKB/Akt [Thr308] of hearts perfused standard KH solution 
containing: 
Ctrl (0): 5mM glucose measured immediately after stabilisation 
Ctrl (10): 5mM glucose measured 10 min after experiment starts. 
Ins (10):5mM glucose and 0.3mIU/mL insulin, measured 10 min after experiment starts. 
LNM (10): 5mM glucose + 0.3mIU/mL insulin and 10μM L-NAME measured 10 min after 
experiment starts. 
 
Phosphorylated PKB/Akt was visualized with an appropriate primary phospho-Akt [Thr308] 
antibody. n = 3 hearts per group. 
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30 MIN 
After 30 min of the experimental protocol, a decrease in phosphorylated 
PKB/Thr308 was observed in the group that received L-NAME. A slight decrease 
was also observed in the control group at the end of the experiment. There was 
no significant difference between the groups. 
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Figure 4.5.b: Phosphorylation of PKB/Akt [Thr308] of hearts perfused standard KH solution 
containing: 
Ctrl (0): 5mM glucose measured immediately after stabilisation 
Ctrl (30): 5mM glucose measured 30 min after experiment starts. 
Ins (30):5mM glucose and 0.3mIU/mL insulin, measured 30 min after experiment starts. 
LNM (30): 5mM glucose + 0.3mIU/mL insulin and 10μM L-NAME measured 30 min after 
experiment starts. 
 
Phosphorylated PKB/Akt was visualized with an appropriate primary phospho-Akt [Thr308] 
antibody. n = 3 hearts per group. 
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EFFECT OF L-NAME ON PHOSPHORYLATED PKB/Akt SERINE 
10 MIN 
The content of phosphorylated PKB/Akt [Ser473] was slightly high in the control 
group and in the group that received insulin 10 minutes after the start of the 
experimental protocol compared to the control group at the beginning of the 
experiment. There was no significant difference in the content of phosphorylated 
PKB/Akt [Ser473] between the control group at the beginning of the experiment 
and the group that received L-NAME 10 min after the beginning of the 
experiment. 
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Figure 4.6.a: Phosphorylation of PKB/Akt [Ser473] of hearts perfused standard KH solution 
containing: 
Ctrl (0): 5mM glucose measured immediately after stabilisation 
Ctrl (10): 5mM glucose measured 10 min after experiment starts. 
Ins (10):5mM glucose and 0.3mIU/mL insulin, measured 10 min after experiment starts. 
LNM (10): 5mM glucose + 0.3mIU/mL insulin and 10μM L-NAME measured 10 min after 
experiment starts. 
 
Phosphorylated PKB/Akt was visualized with an appropriate primary phospho-Akt [Ser473] 
antibody. n = 3 hearts per group. 
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30 MIN 
Thirty minutes after the beginning of the experiment protocol, there was a 
decrease, but not significant, of phosphorylated PKB/Akt [Ser473] of the control 
group. An increase, but not significant, was observed in the group that received 
insulin compared to the other groups. 
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Figure 4.6.b: Phosphorylation of PKB/Akt [Ser473] of hearts perfused standard KH solution 
containing: 
Ctrl (0): 5mM glucose measured immediately after stabilisation 
Ctrl (30): 5mM glucose measured 30 min after experiment starts. 
Ins (30):5mM glucose and 0.3mIU/mL insulin, measured 30 min after experiment starts. 
LNM (30): 5mM glucose + 0.3mIU/mL insulin and 10μM L-NAME measured 30 min after 
experiment starts. 
 
Phosphorylated PKB/Akt was visualized with an appropriate primary phospho-Akt [Ser473] 
antibody. n = 3 hearts per group. 
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EFFECT OF L-NAME ON PHOSPHORYLATED PI3-K 
10MIN 
As expected, an increase, but not significant, in phosphorylated PI3-K was 
observed in the group that received insulin compared to the other groups. There 
was no significant difference on the content of phosphorylated PI3-K between all 
groups. 
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Figure 4.7.a: Activation of PI3-K-p-110α of hearts perfused standard KH solution containing: 
Ctrl (0): 5mM glucose measured immediately after stabilisation 
Ctrl (10): 5mM glucose measured 10 min after experiment starts. 
Ins (10):5mM glucose and 0.3mIU/mL insulin, measured 10 min after experiment starts. 
LNM (10): 5mM glucose + 0.3mIU/mL insulin and 10μM L-NAME measured 10 min after 
experiment starts. 
 
Phosphorylated PI3-K was visualized with an appropriate primary phospho-PI3-K-p-110α 
antibody. n = 3 hearts per group. 
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30MIN 
At 30 minutes of experimental the protocol, an increase, but not significant, of 
phosphorylated PI3-K was observed in the group that received insulin. There 
was no change in the phosphorylated PI3-K content of the control group and the 
group that received L-NAME when compared to phosphorylated PI3-K content 
at 10 min of the experimental protocol. 
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Figure 4.7.b: Activation of PI3-K-p-110α of hearts perfused standard KH solution containing: 
Ctrl (0): 5mM glucose measured immediately after stabilisation 
Ctrl (30): 5mM glucose measured 30 min after experiment starts. 
Ins (30):5mM glucose and 0.3mIU/mL insulin, measured 30 min after experiment starts. 
LNM (30): 5mM glucose + 0.3mIU/mL insulin and 10μM L-NAME measured 30 min after 
experiment starts. 
 
Phosphorylated PI3-K was visualized with an appropriate primary phospho-PI3-K-p-110α 
antibody. n = 3 hearts per group. 
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EFFECT OF WORTMANNIN ON PKB/Akt 
EFFECT OF WORTMANNIN ON TOTAL PKB/Akt 
10 MIN 
Total PKB/Akt was the same in all groups at the beginning as well as at the end 
of the experimental protocol. 
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Figure 4.8.a: Total PKB/Akt of hearts perfused standard KH solution containing: 
Ctrl (0): 5mM glucose measured immediately after stabilisation 
Ctrl (10): 5mM glucose measured 10 min after experiment starts. 
Ins (10):5mM glucose and 0.3mIU/mL insulin, measured 10 min after experiment starts. 
Wort (10): 5mM glucose + 0.3mIU/mL insulin and 100mM wortmannin measured 10 min 
after experiment starts. 
 
Total PKB/Akt was visualized with an appropriate primary antibody. n = 3 hearts per group. 
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Figure 4.8.b: Total PKB/Akt of hearts perfused standard KH solution containing: 
Ctrl (0): 5mM glucose measured immediately after stabilisation 
Ctrl (30): 5mM glucose measured 30 min after experiment starts. 
Ins (30):5mM glucose and 0.3mIU/mL insulin, measured 30 min after experiment starts. 
Wort (30): 5mM glucose + 0.3mIU/mL insulin and 10μM Wortmannin measured 10 min 
after experiment starts. 
 
Total PKB/Akt was visualized with an appropriate primary antibody. n = 3 hearts per group. 
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EFFECT OF WORTMANNIN ON PHOSPHORYLATED PKB/Akt 
THREONINE 
10 MIN 
After 10 minutes of the experimental protocol, the content of PKB/Akt [Thr308] 
was high in the group that received wortmannin compared to all other groups. 
No significant difference was observed between the groups. 
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Figure 4.9.a: Phosphorylated PKB/Akt [Thr308] of hearts perfused standard KH solution 
containing: 
Ctrl (0): 5mM glucose measured immediately after stabilisation 
Ctrl (10): 5mM glucose measured 10 min after experiment starts. 
Ins (10):5mM glucose and 0.3mIU/mL insulin, measured 10 min after experiment starts. 
Wort (10): 5mM glucose + 0.3mIU/mL insulin and 100nM wortmannin measured 10 min 
after experiment starts. 
 
Phosphorylated PKB/Akt was visualized with an appropriate primary phospho-Akt [Thr308] 
antibody. n = 3 hearts per group. 
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30 MIN 
After 30 minutes of the experiment, there was a decrease in the content of 
PKB/Akt [Thr308] in the control group and in the group that received wortmannin, 
but it was not significant. There was no change in the content of PKB/Akt [Thr308] 
of the group that received insulin. 
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Figure 4.9.b: Phosphorylated PKB/Akt [Thr308] of hearts perfused standard KH solution 
containing: 
Ctrl (0): 5mM glucose measured immediately after stabilisation 
Ctrl (30): 5mM glucose measured 30 min after experiment starts. 
Ins (30):5mM glucose and 0.3mIU/mL insulin, measured 30 min after experiment starts. 
Wort (30): 5mM glucose + 0.3mIU/mL insulin and 100nM wortmannin measured 30 min 
after experiment starts. 
 
Phosphorylated PKB/Akt was visualized with an appropriate primary phospho-Akt [Thr308] 
antibody. n = 3 hearts per group. 
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SERINE 
10 MIN 
After 10 minutes of the experimental protocol, the content of phosphorylated 
PKB/Akt [Ser473] was high in the control group and in the group that received 
insulin compared to the control group just after stabilisation. Phosphorylated 
PKB/Akt [Ser473] was lower in the group that received wortmannin. 
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Figure 4.10.a: Phosphorylated PKB/Akt [Ser473] of hearts perfused standard KH solution 
containing: 
Ctrl (0): 5mM glucose measured immediately after stabilisation 
Ctrl (10): 5mM glucose measured 10 min after experiment starts. 
Ins (10):5mM glucose and 0.3mIU/mL insulin, measured 10 min after experiment starts. 
Wort (10): 5mM glucose + 0.3mIU/mL insulin and 100nM wortmannin measured 10 min 
after experiment starts. 
 
Phosphorylated PKB/Akt was visualized with an appropriate primary phospho-Akt [Ser473] 
antibody. n = 3 hearts per group. 
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30 MIN 
After 30 minutes of experiment, there was a slight decrease in phosphorylated 
PKB/Akt [Ser473] content of the control group. The content of phosphorylated 
PKB/Akt [Ser473] in the group that received wortmannin did not varie. No 
significant difference was observed between the groups. 
1
0
Fo
ld
 in
cr
ea
se
Ctrl (0) Ctrl (30) Ins (30) Wort (30)
Fo
ld
 in
cr
ea
se
Fo
ld
 in
cr
ea
se
 
Figure 4.10.b: Phosphorylated PKB/Akt [Serr473] of hearts perfused standard KH solution 
containing: 
Ctrl (0): 5mM glucose measured immediately after stabilisation 
Ctrl (30): 5mM glucose measured 30 min after experiment starts. 
Ins (30):5mM glucose and 0.3mIU/mL insulin, measured 30 min after experiment starts. 
Wort (30): 5mM glucose + 0.3mIU/mL insulin and 100nM wortmannin measured 30 min 
after experiment starts. 
 
Phosphorylated PKB/Akt was visualized with an appropriate primary phospho-Akt [Ser473] 
antibody. n = 3 hearts per group. 
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EFFECT OF WORTMANNIN ON PHOSPHORYLATED PI3K 
10 MIN 
At 10 minutes of the experimental protocol, the content of phosphorylated PI3-K 
was slightly high in the control group and in the group that received insulin, 
compared to the control group at the beginning of the experiment. The group 
that received wortmannin had a low content of PI3-K compared to the insulin 
and the control group. There was no significant difference between the groups. 
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Figure 4.11.a: Phosphorylated PI3-K-p-110α of hearts perfused standard KH solution 
containing: 
Ctrl (0): 5mM glucose measured immediately after stabilisation 
Ctrl (10): 5mM glucose measured 10 min after experiment starts. 
Ins (10):5mM glucose and 0.3mIU/mL insulin, measured 10 min after experiment starts. 
Wort (10): 5mM glucose + 0.3mIU/mL insulin and 100nM wortmannin measured 10 min 
after experiment starts. 
 
Phosphorylated PI3-K was visualized with an appropriate primary phospho- PI3-K-p-110α 
antibody. n = 3 hearts per group. 
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30 MIN 
PI3-K content was still high in the group that received insulin compared to the 
group that received wortmannin and to the control group, 30 minutes after the 
experiment. No significant difference was observed. 
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Figure 4.11.b: Phosphorylated PI3-K-p-110α of hearts perfused standard KH solution 
containing: 
Ctrl (0): 5mM glucose measured immediately after stabilisation 
Ctrl (30): 5mM glucose measured 30 min after experiment starts. 
Ins (30):5mM glucose and 0.3mIU/mL insulin, measured 30 min after experiment starts. 
Wort (30): 5mM glucose + 0.3mIU/mL insulin and 100nM wortmannin measured 30 min 
after experiment starts. 
 
Phosphorylated PI3-K was visualized with an appropriate primary phospho PI3-K-p-110α 
antibody. n = 3 hearts per group. 
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WESTERN BLOTS 
10 MIN 
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Figure 4.12: Representative Western blots of biochemical data 
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Chapter 5 
DISCUSSION 
It is well documented that insulin protects the heart against ischaemia. Sodi-
Pallares et al. were the first in 1962 to perform the pioneering work on the 
cardioprotective effect of insulin against ischaemia. The positive effect of insulin 
on the functional recovery and survival of the ischaemic heart has been the 
focus of several studies. Amongst the major findings are: a reduction in infarct 
size with insulin given at the onset of reperfusion (Jonassen et al., 2000), the 
improved cardiac output recovery during reperfusion (Van Rooyen et al., 1998), 
and the attenuation of apoptosis in rat neonatal cardiomyocytes when insulin 
was administered during reoxygenation (Jonassen et al., 2000).  
 
It was long believed that the effects of insulin involved in its cardioprotection 
such as (i) the enhancement of glycogen synthesis (Lawrence, 1992), (ii) the 
improved protein synthesis (Reif et al., 1997), (iii) the stimulation of glycolysis 
(Depre et al., 1998), (iv) the recruitment of glucose transporters to enhance 
glucose entry into the cells (Coffer et al., 1998), and (v) the positive inotropic 
and positive chronotropic properties (Kearney et al., 1998) were of metabolic 
origin, but lately the emphasis has shifted towards the signal transduction 
pathways downstream of the insulin receptor. The beneficial effects of insulin on 
ischaemia/reperfusion induced injury as well as the pathways involved have 
been studied extensively, however little is known about the effect(s) of insulin 
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and the involvement of the various signalling pathways in the responses seen to 
insulin in the healthy heart under normoxic conditions.  
 
This study was therefore designed to investigate the pathways involved in the 
positive effects of insulin on cardiac function in an isolated healthy heart under 
normoxic conditions with a special regard of the possible involvement of the 
nitric oxide pathway in the effect of insulin on the vasculature and a possible 
involvement of the PI3-K – PKB/Akt pathway on cardiac function, compared to 
the effects of insulin in the isolated ischaemic/reperfused heart model.  
 
PRELIMINARY STUDY 
INSULIN EFFECT ON CARDIAC FUNCTION (HR AND LVDEVP) 
In order to determine a suitable protocol with insulin that best shows the 
beneficial effects of insulin on the heart, a preliminary study was performed to 
determine the suitable dose of insulin to be administered to the heart, via the 
perfusion solution. In previous work done in our laboratory, Louw (Louw 2001, 
Unpublished results, MSc thesis) found that insulin increased cardiac 
contractility before ischaemia. We wanted thus to examine whether her results 
could be repeated, and to see if insulin, at different concentrations, was able to 
exert a protective effect under normoxic conditions without any stressful events 
such as ischaemia. Therefore, we added insulin to the perfusion solution at the 
concentration of 0.3 mIU/mL in one group, 0.6 mIU/mL to a second group and 
1.0 mIU/mL to a third group. We observed that the hearts where insulin was 
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added to the perfusion solution at the concentration of 0.3 mIU/mL gave us a 
constant significant increase in the LVDevP compared to the control group. The 
LVDevP of all insulin groups was higher than the control group (Fig. 4.1.b, p77). 
From the results obtained in our study and on the basis of previous studies that 
used insulin in their protocols (Rosenzweig et al. 1980; Aulbach et al. 1999; 
Jonassen et al. 2001; Louw 2001, Unpublished results, MSc thesis), we 
assumed that insulin at the concentration of 0.3 mIU/mL was the suitable dose 
to be used and we conducted all further experimentation with insulin at the dose 
of 0.3 mIU/mL added to the perfusion solution after a 10 minutes stabilisation 
period of the perfusion protocol. We also hypothesized that the increase in the 
LVDevP that was observed in the groups that received insulin could be 
attributed to the positive inotropic ability of insulin that allows improved 
contraction of the myocardium (Kearney et al., 1998), and thus a better 
developed pressure. 
 
Previous studies showed that the vasodilatory effects of insulin decrease the 
rate of contraction of the myocardium by increasing the vascular tone and the 
left ventricular end diastolic pressure (Oltman et al. 2000; Sundell et al. 2002; 
Westerbacka et al. 2001). Other studies also showed that PI3-K played a role in 
increased contractility in cardiomyocytes (Pitcher et al. 1998; Balligand 1999; 
Koch et al. 2000; Perry & Lefkowitz 2002; Claing et al. 2002; Rockman et al. 
2002) and it is accepted that the cardiomyocytes contraction mediates the 
function of the left ventricle. In those studies, the argument was that the β-
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adrenergic pathway and PKA linked to Ca2+ release from the sarcoplasmic 
reticulum may be involved in the increase of the contraction. Although our model 
and study design were different, it is tempting to assume that in our experiment, 
insulin had similar effects in stimulating the cardiomyocytes leading therefore to 
the increased contraction in hearts receiving insulin alone.  
 
INSULIN EFFECT ON CORONARY FLOW 
It is generally recognised and accepted that insulin is a vasodilator. In our 
preliminary protocol, the coronary flow (CF) of the control group was lower than 
that of the groups that received insulin throughout the experiment. Although not 
significant within the groups where insulin was administered, a dose-dependent 
variation of the coronary flow was observed, with the lower value of CF being 
attributed to the lower concentration of insulin and the higher dose of insulin 
resulting in a higher coronary flow. This means that the vasodilatory effect of 
insulin on the vasculature is dose dependent. These results are consistent with 
that of Sundell and Knuuti (2003) where insulin has been found to be a slow 
vasodilator and that it induces vasodilatation in a time-dependent manner 
(Sundell & Knuuti 2003). 
 
Results of the present study are in accordance with Sundell et al. (2002) who 
demonstrated that insulin induces a dose-dependent increase in hyperaemic 
myocardial blood flow in healthy men. They found that physiological 
hyperinsulinaemia (serum insulin ∼65 mU/L) significantly increased myocardial 
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blood flow and that supra-physiological hyperinsulinaemia (serum insulin ∼460 
mU/L) further enhanced hyperaemic myocardial blood flow (Sundell et al. 2002). 
This confirms that the vasodilatation properties of insulin are dose-dependent. 
 
EFFECT OF L-NAME ON FUNCTION OF HEARTS PERFUSED WITH 
INSULIN 
In the current study, treatment of the hearts with the nitric oxide synthase 
inhibitor L-NAME resulted in a rapid decrease in coronary flow as well as a 
rapide and reversible decrease in heart rate and left ventricular developed 
pressure. This indicates that nitric oxide mediates the effects of insulin on 
cardiac function. Insulin is known to improve cardiac function (Jonassen et al. 
2001; Louw 2001; Van Rooyen et al. 2002) The present study also suggests that 
L-NAME, by inhibiting nitric oxide synthase (NOS), overrides the vasodilatory 
properties of insulin. These results are consistent with previous work  where 
coronary infusion of NOS inhibitors in isolated rat hearts or in humans with 
normal cardiac function resulted in a small but significant reduction in left 
ventricle contractility (Kojda et al. 1997; Cotton et al. 2001).. 
 
L-NAME is a non selective inhibitor of all three NOS isoforms. In the heart, NO is 
constitutively produced by vascular and endocardial endothelium, the 
cardiomyocytes, and the autonomic nerves (Casadei & Sears 2003). Endothelial 
NOS (eNOS) is responsible for vasodilatation and possesses a positive inotropic 
effect under normal conditions (Wunderlich et al. 2003). Studies have 
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demonstrated that basal endogenous NO is an important vasodilator and NOS 
inhibition could increase vascular tone and thus reduce the coronary flow 
(Lieberthal et al. 1991; Naseem et al. 1995). Consistent with these studies, 
results in the present study confirmed the impairment of cardiac function after 
inhibition of NOS by L-NAME. This provisory evidence provides a platform to 
suggest that the inotropic effect of insulin may be linked to the involvement of 
NO in the regulation of the vasculature in our model. 
 
Zeng and Quon have shown that  insulin induces vasodilatation via endothelium 
dependent mechanisms including the L-arginine nitric oxide pathway in human 
umbilical vein endothelial cells (Zeng & Quon 1996). They argued that in 
peripheral vasculature insulin rapidly and dose-dependently stimulates NO 
production in human endothelial cells and that insulin-induced vasodilatation can 
be abolished by inhibitors of eNOS. In accordance with this, administration of L-
NAME together with insulin to hearts resulted in a decrease in coronary flow in 
the present study. This indicates that insulin may stimulate NOS activity in the 
heart under normoxic conditions. 
 
Other findings of the present study were that addition of L-NAME in the insulin 
perfusate had a time dependence effect and that decreases in HR and in 
LVDevP were reversible after cessation of L-NAME administration. The CF did 
not return to normal values at 30 min. This led us to believe that reduction in CF 
was not responsible for the decreases in HR and in LVDevP of hearts that 
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received L-NAME. L-NAME is a non-specific inhibitor of NOS therefore, it will 
inhibit nNOS in the heart. The decrease in function that was observed in the 
present study may also implies that NO is implicated in the inotropic effects of 
insulin on isolated perfused rat heart since inhibition of nNOS will decrease 
LVDevP; and that impairments of function with NOS inhibitors may be reversible 
in the healthy heart. 
 
EFFECT OF WORTMANNIN ON HEARTS PERFUSED WITH INSULIN 
The addition of wortmannin to the perfusion solutions containing insulin resulted 
in a significant impairment of HR, LVDevP and CF. It might be possible that 
wortmannin could abolish the positive inotropic effect of insulin on the 
myocardium, and subsequently induce the loss of the protection offered by 
insulin due to the inhibition of the down-stream signalling pathways leading from 
the insulin receptor (in particular the PI-3-kinase pathway). 
 
PKB 
The metabolic action of insulin is involved in all aspects of the cell. These aspects 
include the increase of glucose uptake from the blood, enhanced conversion to 
glycogen and triacylglycerol, the inhibition of glycogen and fat breakdown, and the 
promotion of protein synthesis (Moule & Denton, 1997). The cardioprotective 
properties of insulin are well known, and the main effects consist of a reduction in 
infarct size when given at the onset of reperfusion (Jonassen, 2000), an improved 
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cardiac output recovery during reperfusion (Van Rooyen, 1998), and the 
attenuation of apoptosis (Jonassen, 2000). 
 
PKB is an important mediator of the physiological effects of insulin. 
Administration of insulin to cells can lead to a 20- to 50-fold activation of kinase 
activity and phosphorylation of PKB (Hemmings, 1997). 
 
In the present study, administration of L-NAME in the insulin perfusion solution 
resulted in an increase in phosphorylation of PKB/Akt [Thr308], immediately after 
L-NAME administration, more than that observed in the group that received 
insulin alone. Phosphorylation of PKB/Akt [Thr308] decreased 20 min later after 
the cessation of administration of L-NAME and perfusion with insulin. This may 
suggests an upstream crosstalk between the NO and PKB/Akt pathways. Our 
results are in accordance with those of Brown et al. (2001) where they found 
that high concentrations of NO led to significant increases in cGMP in aortic 
smooth muscle rat cells. The increase in cGMP led to an increase of Src 
homology 2 phosphatase 2 (SHP2) activity. However, SHP2 is a phosphatase 
that will dephosphorylate PKB/Akt. Therefore, inhibition of NOS with L-NAME 
induces the decrease in NO and this may lead to an increase in PKB/Akt 
phosphorylation. 
 
Administration of wortmannin to the insulin perfusate impaired cardiac function. 
However no difference was observed in the content of phosphorylated PKB/Akt 
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[Thr308] in the group that received wortmannin compared to the insulin and 
control groups. Contrary to phosphorylated PKB/Akt [Thr308], a decrease in the 
content phosphorylated PKB/Akt [Ser473] in the group that received wortmannin 
was more pronounced; although no significant difference could be found. 
 
Several studies indicate that PI3-K is involved in the regulation of PKB. Findings 
from those studies indicate that wortmannin, a specific inhibitor of PI3-K, inhibits 
insulin-induced activation of PKB (Franke et al., 1995; Burgering & Coffer, 1995; 
Kohn et al., 1995). 
 
In agreement with the results that indicated a role for PI3-K in the activation of 
PKB (Franke et al., 1995; Burgering & Coffer, 1995; Kohn et al., 1995), the 
current study showed that wortmannin reduced the phosphorylation of PKB. 
Although not significant, we concluded that in healthy hearts, phosphorylation of 
PKB is also mediated via a PI3-K pathway like in the reperfused hearts. 
 
Although addition of wortmannin to insulin resulted in a complete decrease in the 
LVDevP and in the coronary flow, it did not abolish phosphorylation of PI3-K in the 
present study. This indicates that the increased inotropic effects could be 
mediated via a pathway different from the insulin induced PI3-K activation. 
Previous studies have shown that PKB/Akt could be activated by increases in 
intracellular cAMP in a manner that is independent of PI3-K (Sable et al. 1997; 
Konishi et al. 1997; Filippa et al. 1999). Agents that could increase intracellular 
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levels of cAMP could activate PKB/Akt in transfected 293 cells (Sable et al. 1997). 
Filippa et al (1999) demonstrated that the kinase responsible for this activation 
was the protein kinase A (PKA). This is not surprising, since virtually all the effects 
of cAMP are mediated by PKA (Filippa et al. 1999). 
In the present study, the decrease in PI3-K activation was associated with an 
increase in phosphorylated PKB/Akt [Ser473] in hearts that received insulin + L-
NAME. One would expect PKB/Akt [Ser473] to be decreased if PI3-K activation is 
decreased (Jonassen et al. 2001; Louw 2001, Unpublished results, MSc thesis; 
Jonassen et al. 2004). However, cAMP may also phosphorylate PKB/Akt (Sable 
et al. 1997; Konishi et al. 1997; Filippa et al. 1999). Louw (2001) found in her 
study that insulin increased cAMP during low flow ischaemia. She demonstrated 
that there was a cross signalling from the insulin cascade to production of cAMP, 
a messenger normally associated with β-adrenergic stimulation (Louw 2001). 
Therefore, we suggest that PKB/Akt may be phosphorylated by cAMP and also 
via the NO/cGMP pathway in our model. 
 
Although cAMP was not measured in the present study, it is tempting to speculate 
that cAMP stimulation of PKA led to phosphorylation of PKB/Akt. 
 
It has been demonstrated in previous studies that insulin increased the cAMP 
and cGMP content in human vascular smooth muscle cells (Trovati et al. 1995) 
and that insulin and EGF activate the adenyl cyclase system in a bivalve mollusc 
(Pertseva et al. 1995). Based on this information, we speculate that the increase 
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in contractility in the group where insulin was administered alone could result not 
only from the direct insulin effect on LVDevP but also from the NO mediated 
increase in contractility via cGMP or from the β-adrenergic stimulation of cAMP 
that stimulates PKA and induces PKB/Akt phosphorylation. From the observed 
results in the present study, we also suggest that the increase in contractility in 
hearts that received insulin alone may also result from additive effects of all 
above mentioned pathways, including cAMP, NO and cGMP, which mediate the 
increase in contraction in hearts receiving insulin alone. 
 
The mechanisms of insulin-induced vasodilatation are well characterized. They 
have been studied mainly in peripheral vasculature (Laakso et al. 1990; Baron 
1994; Utriainen et al. 1995). We were unable to find any documented data on 
the signalling pathways of insulin on normoxic perfused isolated rat heart 
function or data describing the mechanisms of the effect of insulin-induced 
vasodilatation on the heart. To the best of our knowledge, this is the first study 
that set a protocol to investigate insulin pathways in normoxic perfused isolated 
rat hearts. Therefore, further research should be carried out in this regard in the 
attempt of clarifying the signalling pathways involved in insulin cardioprotection 
in hearts under normoxic condition. 
 
Limitations of our study 
Although this study set out to investigate the insulin pathways involved in the 
cardioprotection in normoxic conditions, our protocols showed some limitations.  
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L-NAME is an inhibitor of NOS. Therefore, inhibition of NOS leads to a decrease 
in NO, compared to the baseline values. The decrease in NO induces a decrease 
in coronary flow, thus a decrease in oxygen and glucose provision to the heart. 
We therefore perfused with L-NAME for 10 minutes because we speculated that 
NOS was sufficiently inhibited. The best way would have been to provide L-NAME 
throughout the protocol. Also the fact that we did not measure PI3-K and PKB/Akt 
constantly at several different time points might not have allowed us to draw a 
definitive conclusion. Phosphorylation of PI3-K and PKB/Akt may occur within the 
first 5 minutes after the beginning of the experiment while we investigated only the 
baseline state and the values of phosphorylated PI3-K and PKB/Akt at the end of 
our protocol. 
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CONCLUSIONS 
The results obtained in the present study showed that a dose of 0.3 mIU/mL 
provided a constant positive inotropic effect in the heart. The beneficial effects of 
insulin were observed here by a constant increase in the left ventricular 
developed pressure (LVDevP). In this study, L-NAME exerted a negative effect 
on cardiac function by decreasing the heart rate (HR) and LVDevP as well as 
the coronary flow (CF). In the insulin+L-NAME group, the negative inotropic 
effects were reversed during reperfusion with insulin. This may indicate that 
nitric oxide (NO) has a role in the effect of insulin on cardiac function. The 
present study confirmed the detrimental effect of wortmannin on hearts since the 
LVDevP and the CF were decreased in the group that received wortmannin. 
 
We furthermore conclude that, in contrast to the role that the PI3-K – PKB/Akt – 
p70s6k pathway plays in the protective effects of insulin during 
ischaemia/reperfusion, activation of NOS and production of NO is the dominant 
signalling pathway of the effects of insulin during normoxic perfusion. 
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APPENDIX 1 
 
SALT BUFFERS 
 
PERFUSION BUFFER: KREBS HENSELEIT 
 Reagents  Concentrations 
 NaCl   119 mM 
 NaHCO3  25 mM 
 KH2PO4  1.2 mM 
 KCl   4.7 mM 
 MgSO4-7H2O 0.59 mM 
 CaCl2-2H2O  1.25 mM 
 Glucose  5 mM 
 
PROTEINS SEPARATION BUFFERS 
¾ LYSIS BUFFER 
 Reagents  Concentrations 
 Tris-Base  20 mM 
 pNPP   20 mM 
 NaF   50 mM 
 DTT   1 mM 
 EGTA   1 mM 
 PMSF   1 mM 
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 NaVO4  0.1 mM 
 Aprotinin  10 μg/ml 
 Leupeptin  10μg/ml 
 
¾ LAEMMLI (SAMPLE BUFFER) 
Reagents   Concentrations 
Tris    0.5M 
SDS    0.4% 
Glycerol 
Bromo phenol Blue 
β-mercaptoethanol 
 
¾ RUNNING BUFFER 
Reagents  Concentrations 
Tris   50mM 
Glycine  384mM 
SDS   10% 
 
¾ BLOTTING BUFFER 
Reagents  Concentrations 
Tris   25mM 
Glycine  192mM 
Methanol  20% 
  157
GELS BUFFERS 
Mini-gel system 
Reagents  Concentrations 
 Tris-HCl (pH 8.8) 1.5M 
 Tris-HCl (pH 6.6) 0.5M 
 SDS   10% 
 Acrylamide  40% 
 APS   10% 
 Temed 
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APPENDIX 2 
ABBREVIATION 
β-AR     Beta-adrenergic receptor 
β-ARK1    Beta-adrenergic receptor kinase-1 
β-FGF     Beta fibroblast growth factor 
A     Agonist 
AC     Adenyl cyclase 
ADP     Adenosine di-phosphate 
AMI     Acute myocardial infarction 
ANOVA    Analysis of variance 
AP-2     Adaptor protein-2 
aPKC     Atypical protein kinase C 
APS     Ammonium persulfate 
AR     Adreno-receptor 
ATP     Adenosine tri-phosphate 
cAMP     Cyclic adenosine monophosphate 
CF     Coronary flow 
cGMP     Cyclic guanosine monophosphate 
DP     Diastolic pressure 
DTT     dithiotreitol 
EC     Excitation–contraction 
eNOS     Endothelial nitric oxide synthase 
ERK     Extracellular signal-related kinases 
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FFA     Free fatty acids 
GF     Growth factor 
GIK     Glucose-insulin-potassium 
Gluc     Glucose 
GLUT-1    Glucose transporter 1 
GLUT-4    Glucose transporter 4 
GPCR     G protein coupled receptor 
GS     Glycogen synthase 
GSK-3    Glycogen synthase kinase-3 
HBGF     Heparin binding growth factor 
HR     Heart rate 
hsp90     Heat-shock protein (90kDa) 
IGF-1     Insulin-like growth factor 1 
IGF-IR    Insulin-like growth factor 1-insulin receptor 
iNOS     Inducible nitric oxide synthase 
Ins     Insulin 
IR     Insulin receptor 
IRS-1/2    Insulin receptor substrate-1/2 
JNK     c-Jun N-terminal protein kinase 
KH     Krebs-Henseleit 
L-NAME    Nω- nitro - L -arginine-methyl ester 
LNM     L-NAME 
LPS     Lipopolysaccharide 
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LVDevP    Left ventricular developed pressure 
MAP     Mitogen activated kinase 
mTOR    Mammalian target of Rapamycin 
NADPH    Nicotinamide adenine dinucleotide phosphate 
(reduced form) 
NaF     Sodium fluoride 
NaVO2    Sodium orthovanadate 
NGF     Nerve growth factor 
NMDA    N-methyl-D-asparate 
nNOS     Neuronal nitric oxide synthase 
NO     Nitric oxide 
NOS     Nitric oxide synthase 
p38 MAP    p38 mitogen activated protein 
PCD     Programmed cell death 
PDE     Phosphodiesterase 
PDGF     Platelet-derived growth factor 
PDK-1/2    Phosphoinositide-dependent protein kinase-1/2 
PFK2     Phosphofructokinase-1/2 
PH     Pleckstrin homology 
PI3-K     Phosphatidylinositol 3-kinase 
PKA     Protein kinase A 
PKB     Protein kinase B 
PKC     Protein kinase C 
PKG     cGMP-dependent protein kinase 
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PLB     Phospholamban 
PMSF     phenylmethyl sulphonyl fluoride 
pNPP     p-nitrophenylphosphate 
PP-1     Protein phosphatise-1 
PtdIns    Phosphatidylinositols 
PVDF     Polyvinylidenedifluoride 
RyR2     Ryanodine receptor 
SDS-PAGE    Sodium dodecyl sulfate-polyacrylamide  
     electrophoresis 
SEM     Standard error of the mean 
SERCA    Sarco(endo)plasmic reticulum Ca2+ ATPase 
SHP2     Src homology 2 phosphatase 2 
SP     Systolic pressure 
SR     Sarcoplasmic reticulum 
Wort     Wortmannin 
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